Clinical trial NCT05382936
Conditions: Advanced Solid Tumor
Sponsor: Stemline Therapeutics, Inc.
Start date: 2021-03-19; Completion date: 2023-05-05
Enrollment: 20 participants; Allocation: NON_RANDOMIZED; Intervention model: PARALLEL

Brief summary:
Study STML-901-0119 was a dose-escalation study evaluating multiple doses and schedules of orally administered SL-901 in patients with advanced solid tumors.

Detailed description:
Study STML-901-0119 was a multi-center, open-label, dose-escalation, and regimen-finding study aimed to investigate the safety, pharmacokinetics (PK), and pharmacodynamics of SL-901 in patients with advanced solid tumors. This study initially included two parts: Part 1a, which used a 3+3 dose-escalation design to determine the maximum tolerated dose and an appropriate dosing regimen of SL-901 when administered on both once-daily (QD) and twice-daily (BID) schedules; Part 1b, which was intended to evaluate the clinical activity of SL-901 at the selected dose in patients with advanced solid tumors with specific genetic alterations.

The study was stopped after careful consideration of the landscape of similar drugs and evolving standard of care. As a result, Part 1b was not initiated. In Part 1a, eligible patients were enrolled to receive SL-901 orally on a 28-day cycle. Study enrollment was conducted in 2 centers in the United Kingdom, and patients were assigned to either the QD or BID dosing regimen based on their cohort assignment.

Arms: arm 1: Patients in the QD regimen took study medication once daily. arm 2: Patients in the BID regimen took study medication twice daily.
Interventions: intervention 1: SL-901
Intervention descriptions: intervention 1: Patients took study medication daily, with dosage based on their assigned cohort and regimen.

Protocol documents:
Prot_000.pdf: 
Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
Stemline Therapeutics, Inc.
A Phase 1, Open-label, Dose-escalation Study of the PI3K Inhibitor SL-901 in Patients
with Advanced Solid Tumors
Protocol Number: STML-901-0119
This study will be conducted according to the protocol and in compliance with
Good Clinical Practice, the ethical principles stated in the Declaration of Helsinki,
and other applicable regulatory requirements.
Study Sponsor:
Sponsor Signatory:
Document Version (Date):
Previous Version (Date):
Stemline Therapeutics, Inc.
750 Lexington Ave.
4thth Floor
New York, NY 10022
Stemline Therapeutics, Inc.
Email: 
Version 3.0 (13 October 2022)
Version 2.0 (06 October 2020)
Version 1.0 (04 August 2020)
Restricted Distribution of Documents
This document contains information that is confidential and proprietary to Stemline
Therapeutics, Inc. (“Stemline” or the “Company” or the “Sponsor”). This information is being
provided to you solely for the purpose of evaluating and/or conducting a clinical study for the
Sponsor.
You may disclose the contents of this document only to study personnel under your
supervision, institutional review boards (IRBs)/independent ethics committees (IECs), or duly
authorized representatives of regulatory agencies for this purpose under the condition that they
maintain confidentiality.
The contents of this document may not be used in any other clinical study, disclosed to any
other person or entity, and/or published without the prior written permission of the Sponsor.
The foregoing shall not apply to disclosure required by any regulations; however, you will give
prompt notice to the Sponsor of any such disclosure.
Confidential
Page 1 of 56
.
NCT #: NCT05382936


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
PROTOCOL SIGNATURE PAGE
Protocol Title:
Protocol Version & Date
A Phase 1, Open-label, Dose-escalation Study of the PI3K
Inhibitor SL-901 in Patients with Advanced Solid Tumors
Version 3.0, 13 October 2022
Investigator Statement
I understand that all documentation provided to me by the Sponsor or its designated
representative(s) concerning this study that has not been published previously will be
kept in the strictest confidence. This documentation includes the study protocol,
Investigator’s brochure, case report forms, and other scientific data.
This study will not commence without the prior written approval of a properly constituted
Ethics Committee (EC)/Institutional Review Board (IRB) and national regulatory
approval. No changes will be made to the study protocol without the prior written
approval of the Sponsor and the EC/IRB, except where necessary to eliminate an
immediate hazard to the patient.
I have read, understood and agree to abide by all the conditions and instructions
contained in this protocol.
Principal Investigator:
Print Name
Signature & Date
Institution
Stemline Therapeutics, Inc:
Print Name
Signature & Date
Title
Confidential
)
Page 2 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
Abbreviation
AE
AKT (PKB)
ALT
ANC
AST
ATP
BID
BP
C
CFR
CMP
CONSORT
CR
CRA
eCRF
CTCAE
D
DCR
DLT
DNA-PK
DOCR
DOR
EC
ECG
ECOG
EDC
EOT
FPG
GCP
GPCR
GSK3
HDPE
HED
IC50
Confidential
LIST OF ABBREVIATIONS
Description
Adverse event
RAC-alpha serine/threonine-protein kinase (protein kinase B)
Alanine aminotransferase
Absolute neutrophil count
Aspartate aminotransferase
Adenosine triphosphate
Twice daily
Blood pressure
Cycle
Code of federal regulations
Clinical Monitoring Plan
Consolidated Standards of Reporting Trials
Complete response
Clinical Research Associate
Electronic case report form
Common Terminology Criteria for Adverse Events
Day
Disease control rate
Dose-limiting toxicity
Deoxyribonucleic acid-dependent protein kinase
Duration of complete response
Duration of response
Ethics committee
Electrocardiogram
Eastern Cooperative Oncology Group
Electronic data capture
End-of-Treatment
Fasting plasma glucose
Good Clinical Practice
G protein coupled receptors
Glycogen synthase kinase 3
High-density polyethylene
Human equivalent dose
50% inhibitory concentration
Page 3 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
Abbreviation
ICF
ICH
IME
IRB
ITT
MedDRA
MTD
mTOR
NCI
NFG
NOAEL
ORR
OS
p-AKT
PBMC
PD
PFS
p-GSK3
PI3K
PIP2
PIP3
PK
p-p70S6K
PR
PT
PTEN
QC
QD
RBC
RECIST v1.1
RTK
SAE
Confidential
Description
Informed consent form
International Council for Harmonisation
Important medical event
Institutional review board
Intent-to-treat
Medical Dictionary for Regulatory Activities
Maximum tolerated dose
Mammalian target of rapamycin
National Cancer Institute
Non-fasting glucose
No observed adverse effect level
Objective response rate
Overall survival
Phosphorylated-RAC-alpha serine/threonine-protein kinase (protein
kinase B)
Peripheral blood mononuclear cell
Pharmacodynamics
Progression-free survival
Phosphorylated glycogen synthase kinase 3
Phosphoinositide 3-kinase
Phosphatidylinositol diphosphate
Phosphatidylinositol triphosphate
Pharmacokinetics
Phosphorylated p70S6 kinase
Partial response
Preferred term
Phosphatase and tensin homolog
Quality control
Once daily
Red blood cell
Response Evaluation Criteria in Solid Tumors, version 1.1
Receptor tyrosine kinase
Serious adverse event
Page 4 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
Abbreviation
SUSAR
TEAE
ULN
Confidential
Description
Suspected unexpected serious adverse reaction
Treatment-emergent adverse event
Upper limit of normal
Page 5 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
TABLE OF CONTENTS
PROTOCOL SIGNATURE PAGE..................................................................................2
LIST OF ABBREVIATIONS ...........................................................................................3
TABLE OF CONTENTS ..................................................................................................6
LIST OF TABLES...........................................................................................................10
LIST OF FIGURES.........................................................................................................10
1.         PROTOCOL SUMMARY ..................................................................................11
1.1.      Synopsis.....................................................................................................11
1.2.      Schedule of Assessments...........................................................................16
2.         INTRODUCTION................................................................................................20
2.1.      Background................................................................................................20
2.1.1.       Phosphoinositide 3-Kinases (PI3K) as a Cancer Target.............20
2.1.2.       SL-901 ........................................................................................21
2.2.      Rationale for Current Study and Risk/Benefit Assessment.......................22
3.         OBJECTIVES AND ENDPOINTS ....................................................................24
4.         STUDY DESIGN..................................................................................................25
4.1.      Overall Design and Operational Characteristics........................................25
4.1.1.       Dose-Escalation (Part 1a) ...........................................................25
4.1.2.       Expansion Cohorts (Part 1b).......................................................25
4.1.3.       Justification for Study Design.....................................................26
5.         STUDY POPULATION ......................................................................................27
5.1.      Inclusion Criteria .......................................................................................27
5.2.      Exclusion Criteria ......................................................................................27
5.3.      Screen Failures...........................................................................................28
5.4.      Source of Patients ......................................................................................28
6.         STUDY DRUG .....................................................................................................29
6.1.      Study Drug Supply.....................................................................................29
6.2.      Study Drug Packaging and Storage ...........................................................29
6.3.      Study Drug Accountability ........................................................................29
6.4.      SL-901 Dose and Administration ..............................................................29
6.4.1.
6.4.2.
Confidential
Dose-Escalation Scheme in Part 1a ............................................30
Dose-Limiting Toxicities............................................................31
Page 6 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
6.4.3.       Operational Characteristics of Dose-Escalation .........................32
6.5.      Rationale for the Dose(s) Selected.............................................................32
6.6.      Dose Interruptions and Reductions............................................................33
6.6.1.       Intra-Patient Dose-Escalation .....................................................33
7.         STUDY INTERVENTION DISCONTINUATION AND PATIENT
DISCONTINUATION/WITHDRAWAL ..........................................................34
7.1.      Patient Withdrawal and Replacement........................................................34
7.2.      Dose Modifications....................................................................................34
7.3.      Treatment Discontinuation.........................................................................34
7.4.      Lost to Follow-Up......................................................................................35
8.         STUDY ASSESSMENTS ....................................................................................36
8.1.      Screening Assessments..............................................................................36
8.1.1.       Demographic Data, Medical History, ECOG Performance Status,
and Cancer History .....................................................................36
8.1.2.       Prior Medications........................................................................36
8.1.3.       Contraception, Pregnancy and Pregnancy Testing .....................36
8.1.4.       Physical Examination .................................................................37
8.2.      Adverse Events and Serious Adverse Events ............................................38
8.2.1.       Definitions ..................................................................................38
8.2.2.       Adverse Event Assessment and Reporting.................................39
8.2.3.       Reporting Serious Adverse Events .............................................41
8.2.4.       Special Cases: Overdose and Pregnancy ....................................42
8.2.5.       Protocol Deviations Due to an Emergency or Adverse Event....42
8.3.      Laboratory Assessments ............................................................................42
8.4.      Weight and Vital Signs..............................................................................43
8.5.      Concurrent Medications.............................................................................43
8.5.1.       Prohibited Concurrent Medications............................................43
8.5.2.       Permitted Concurrent Medications.............................................44
8.5.3.       Additional Important Considerations..........................................44
8.6.
8.7.
8.8.
Confidential
Pregnancy...................................................................................................44
Tumor Assessments ...................................................................................44
Pharmacokinetics.......................................................................................45
Page 7 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
      
      
8.9.      Electrocardiogram......................................................................................46
8.10.    Pharmacodynamics ....................................................................................46
9.         STATISTICAL CONSIDERATIONS ...............................................................47
9.1.      Statistical Basis for Sample Size................................................................47
9.2.      Populations for Analysis............................................................................47
9.3.      Statistical Analysis Plan.............................................................................47
9.3.1.       Patient Disposition......................................................................47
9.3.2.       Demographic and Baseline Characteristics ................................48
9.3.3.       Concurrent Medications..............................................................48
9.3.4.       Safety Analyses...........................................................................48
9.3.5.       Efficacy Analyses .......................................................................49
9.3.6.       Pharmacokinetic Analysis...........................................................50
9.3.7.       Electrocardiogram Analysis........................................................51
9.3.8.       Pharmacodynamic Analysis........................................................51
9.4.      Changes to the Planned Statistical Methods..............................................51
10.       SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS...........................................................................................52
10.1.    Ethical, Legal, and Administrative Considerations ...................................52
10.1.1.
10.1.2.
10.1.3.
10.1.4.
10.1.5.
10.1.6.
10.1.7.
10.1.8.
10.1.9.
Informed Consent .......................................................................52
Study Discontinuation and Closure ............................................52
Confidentiality and Privacy ........................................................52
Future Use of Stored Specimens and Data .................................53
Key Roles and Study Management.............................................53
Clinical Monitoring.....................................................................53
Quality Assurance and Quality Control......................................53
Data Handling and Record Keeping...........................................54
Protocol Deviations.....................................................................54
10.1.10. Publication and Data Sharing Policy ..........................................55
10.1.11. Financial Disclosure Reporting Obligations...............................55
Confidential
Page 8 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
11.       REFERENCES.....................................................................................................56
Confidential
Page 9 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
Table 3:
Table 4:
Table 5:
Table 6:
Table 7:
Table 8:
Figure 1:
Confidential
LIST OF TABLES
Summary of IC50 Values and Targets for Approved PI3K Inhibitors and
SL-901........................................................................................................23
Study Objectives and Endpoints................................................................24
Planned SL-901 Dose Levels in Part 1a ....................................................25
Management of Unusual Non-Autoimmune and Non-Infectious Toxicities
....................................................................................................................33
Clinical Laboratory Parameters to be Measured During the Study...........43
Time Points for Pharmacokinetic and Electrocardiogram Assessments....46
LIST OF FIGURES
PI3K/AKT/mTOR Signaling Pathway Schema.........................................21
Page 10 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
1.
PROTOCOL SUMMARY
1.1.
Synopsis
Protocol Title:
Protocol Number:
Study Phase:
Study Centers:
Study Population
Study Objectives:
A Phase 1, Open-label, Dose-escalation Study of the PI3K Inhibitor
SL-901 in Patients with Advanced Solid Tumors
STML-901-0119
Phase 1
Approximately 25 centers in the United States, United Kingdom and
Europe
In Part 1a, patients with advanced solid tumors, to determine the
regimen for Part 1b. In Part 1b, the clinical activity of SL-901 will be
evaluated in patients with advanced solid tumors known to have specific
genetic alterations, who may derive benefit from treatment with a
phosphoinositide 3-kinase (PI3K) inhibitor.
This is a two-part study: In Part 1a, escalating doses and 2 schedules
(once daily [QD] and twice daily [BID]) of SL-901 will be evaluated.
In Part 1b, the clinical activity of SL-901 at the selected dose and
schedule will be evaluated.
Primary Objective:
1) To identify the maximum tolerated dose (MTD) of SL-901.
2) To identify an appropriate dosing regimen for further
investigation of SL-901.
3) To characterize the pharmacokinetics (PK) profile of SL-901.
4) To generate clinical safety data and perform initial assessment
of the safety profile of SL-901.
Secondary Objectives:
1) To characterize the pharmacodynamics (PD) of SL-901 in
blood and tissue.
2) To assess preliminary clinical activity of SL-901.
Study Design:
This clinical study includes 2 parts:
1) Part 1a: An open-label, dose-escalation and regimen-finding to
investigate the safety, PK, and PD of SL-901 in patients with
advanced solid tumors. In Part 1a, adverse events (AEs)
occurring during the first cycle of treatment will be considered
for the assessment of dose-limiting toxicities (DLTs), with
continued evaluation of AEs in subsequent treatment cycles for
further characterization of the safety of SL-901. This part will
follow a 3+3 dose-escalation design to determine the MTD of
SL-901 when administered on each a QD and BID schedule;
single and multiple dose PK assessments will be performed to
characterize the exposure of SL-901.
2) Part 1b: Up to 4 expansion cohorts of patients with specific
genetic alterations that may derive benefit from treatment with
a PI3K inhibitor will be treated SL-901 with the dose regimen
selected in Part 1a.
This study will explore different dose levels and schedules of SL-901
given as a single agent, therefore the term “regimen” is comprised of the
Confidential
Page 11 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
unit dose administered and the specified schedule of dosing in a given
cohort.
A treatment cycle is 28 days, with daily dosing throughout the cycle.
·
 In Part 1a, 3 to 6 patients may be enrolled in each regimen to be
investigated. Schedules will include QD or BID
administrations, as described in Table 5 for each specified dose
level.
·
 In Part 1b, 6 to 12 patients may be enrolled in each expansion
cohort (up to 4 expansion cohorts may be opened for
enrollment).
“Number of Patients
Planned:
Diagnosis and Main
Criteria for Inclusion:
Patients may continue to receive SL-901 until disease progression or
unacceptable toxicity.
Dose-Escalation Rules:
In Part 1a of the study, AEs occurring during the first cycle of treatment
will be considered for the assessment of DLTs, with continued
evaluation of AEs in subsequent treatment cycles for further
characterization of the safety of SL-901. Further assessment of the
safety of SL-901 at the recommended regimen from Part 1a will be
performed in Part 1b.
Upon occurrence of a DLT in the first 3 patients of a given cohort
dosing schedule, up to 3 additional patients will be added to that cohort
dosing schedule. In the resulting 6-patient cohort dosing schedule, dose-
escalation to a higher dose will occur when all 6 patients in that dosing
schedule have completed the first cycle of SL-901, and no additional
DLTs have occurred. If two or more DLTs occur in a given cohort
dosing schedule, a DLT is established and the next lower dose level will
be declared the MTD for that dosing schedule. See Section 6.4.2 for
DLT definition.
All dose-escalation steps and schedule recommendations will be made
by a review committee, comprised of the study Investigators and
Sponsor representatives, who will review the available safety and other
relevant data to inform the decision on escalating to a higher dose level
(see Section 4.1.1). Refer to the Data Safety Review Charter (DSRC) for
further details.
For each dosing schedule, 3 to 6 patients are to be enrolled in each dose-
escalation cohort in Part 1a. Up to 60 patients in total are to be enrolled
in the dose-escalation cohorts.
Six to 12 patients in each expansion cohort (up to 4 cohorts) are to be
enrolled in Part 1b.
Patients meeting all the following criteria will be considered eligible
for study entry:
1) 18 years old or older.
2) Population by study stage:
a.
Part 1a: Patients with advanced, metastatic, and/or progressive
solid tumors for whom there is no effective standard therapy
available.
b.
Part 1b: Patients with histologically confirmed, advanced,
metastatic, unresectable, and/or progressive solid tumors for
whom there is no effective standard therapy available and their
PI3K or deoxyribonucleic acid-protein kinase (DNA-PK)
Confidential
Page 12 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
pathway is deregulated or their tumor genetic profile has been
shown to correlate with sensitivity to PI3K and/or DNA-PK
inhibition based on clinical and preclinical experience. Specific
criteria will be determined based on ongoing experiments and
will be introduced in a future protocol amendment.
3) Evaluable or measurable disease.
4) Eastern Cooperative Oncology Group (ECOG) performance status
≤2.
5) Able to take oral medications.
6) If a woman of childbearing potential (WOCBP), the patient has a
negative serum or urine pregnancy test within 1 week before
Cycle 1, Day 1 (C1D1). Refer to Section 8.1.3 for further practical
information about contraception.
7) The patient (either male or female) agrees to use acceptable
contraceptive methods for the duration of time in the study, and to
continue to use acceptable contraceptive methods for 1 month after
the last dose of SL-901. Refer to Section 8.1.3 for further practical
information about contraception.
8) Able to provide written informed consent.
9) Willing to provide consent for biomarker analysis of (existing
paraffin-embedded) tumor samples.
Confidential
Page 13 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
Patients meeting any of the following criteria will be excluded from
the study:
1) Received an investigational anticancer drug within 4 weeks of the
first planned SL-901 dose.
2) Received major surgery, radiotherapy, or immunotherapy within
4 weeks of C1D1. Localized palliative radiotherapy is permitted for
symptom control.
3) Received chemotherapy regimens with delayed toxicity within
4 weeks (6 weeks for prior nitrosourea or mitomycin C) of C1D1.
4) Received chemotherapy regimens given continuously or on a
weekly basis which have limited potential for delayed toxicity
within 2 weeks of C1D1.
5) Clinically significant, unresolved toxicity from previous anticancer
therapy ≥Grade 2 (except alopecia), as determined by the
Investigator using the National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI CTCAE), version
5.0.
6) Presence of active gastrointestinal disease or other condition that
will interfere significantly with the absorption, distribution,
metabolism, or excretion of drugs.
7) Left ventricular ejection fraction <50%.
8) Corrected QT interval (based on Fridericia’s formula) >450 msec.
9) Type 1 or 2 diabetes mellitus requiring medication. (In Part 1b,
patients with type 2 diabetes mellitus controlled by medication, as
indicated by a glycated hemoglobin of ≤7.5% are eligible.)
Test Products, Doses,
and Mode of
Administration:
Duration of Treatment:
Confidential
10) Known active human immunodeficiency virus, hepatitis B, or
hepatitis C infection.
11) Ongoing systemic bacterial, fungal, or viral infection.
12) History of interstitial pneumonitis.
13) Absolute neutrophil count (ANC) <1.5´109/L.
14) Hemoglobin <10 g/dL.
15) Aspartate aminotransferase (AST) or alanine aminotransferase
(ALT) >2.5´ the upper limit of normal (ULN).
16) Known hypersensitivity or allergy to the active ingredient or
excipients of SL-901.
17) Breast-feeding females.
In Part 1a, the SL-901 starting dose on the 20 mg on both the QD and
BID schedule. Dose levels planned to be tested in both QD and BID
schedules will be tested in parallel, with enrollment to the current cohort
for each schedule conducted on an every other patient basis (see
Table 5).
A treatment cycle is 28 days, with daily dosing throughout the cycle.
The regimen of SL-901 for Part 1b of the study will be based on the
clinical experience from Part 1a.
Patients whose disease has not progressed and who have not
discontinued due to toxicity, may continue to receive additional cycles
of SL-901 at the same dose and schedule.
Page 14 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
Safety:
Efficacy:
Statistical Methods:
Confidential
Patients’ medical history will be collected during Screening and updated
prior to the first SL-901 dose. Safety assessments include physical
examinations, safety laboratories (clinical chemistry, hematology, and
coagulation), vital signs and weight, ECOG performance status, and
electrocardiograms (ECGs) (performed according to the schedule in
Table 8). Assessment of AEs and concomitant medications will be
performed for each patient throughout the study.
An End-of-Treatment (EOT) visit to include safety laboratory evaluation
plus adverse events and concomitant medication checks, will be
conducted 30 days after the last dose of SL-901.
Tumor assessment by will occur at Screening (for identification of
baseline disease) and after every 2 cycles of treatment thereafter.
Response will be evaluated using Response Evaluation Criteria in Solid
Tumors (RECIST) v1.1 (Eisenhauer 2009).
After completion of the EOT visit, patients will then be followed every
90 days for survival status for 12 months. The survival follow-up may
be by telephone contact. If the patient discontinued study drug for
reasons other than progressive disease, disease assessments should
continue to be performed on an every 8-week basis (±1 week) through
6 months after the first study drug dose and then on an every 90-day
basis or until, in the judgment of the Investigator, there is evidence of
relapsed or progressive disease.
Study data will be reviewed in accordance with the Statistical Analysis
Plan described in Section 9.3.
Page 15 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
1.2.
Schedule of Assessments
Confidential
Page 16 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
Confidential
Page 17 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
Confidential
Page 18 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
Confidential
Page 19 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
2.
INTRODUCTION
2.1.
Background
2.1.1.
Phosphoinositide 3-Kinases (PI3K) as a Cancer Target
PI3K enzymes are a family of lipid kinases that phosphorylate the 3-hydroxyl group of
the inositol ring of phosphoinositols. The most important product of this process is
phosphatidylinositol-3,4,5- triphosphate, that serves as a secondary messenger that
triggers fundamental cellular processes such as cell growth, survival, motility and
metabolism. PI3K isoforms phosphorylate phosphatidylinositol diphosphate (PIP2) to
phosphatidylinositol triphosphate (PIP3), which is a secondary messenger that triggers
the activation of other downstream kinases such as RAC-α serine/threonine-protein
kinase (AKT), glycogen synthase kinase 3 (GSK3)-β and mammalian target of rapamycin
(mTOR) (see Figure 1). Dysregulated PI3K signaling in cancers is typically manifested
as constitutive signaling of the pathway, either because of mutated upstream membrane
receptors, gain of function mutations in the PI3K gene, or loss of function mutations in
the gene encoding the phosphatase and tensin homolog (PTEN) phosphatase, which acts
as a negative-regulator of the signaling pathway by removing a critical phosphate from
the inositol moiety of PIP3, thereby inhibiting the signaling cascade downstream of PIP3
(Courtney 2010).
The importance of the PI3K pathway for tumorigenesis is evidenced by the high
frequency of overactive PI3K signaling in a variety of malignancies from different tissues
of origin (Liu 2009):
·
Critical point mutations in the PIK3CA gene, encoding for the p110-α catalytic
subunit of PI3K-α, were commonly found in breast (27%), endometrial (24%),
urinary tract (17%), colon (15%), and upper digestive tract (11%) cancers, and in
2% to 9% of skin, stomach, ovaries, liver, brain, oesophagus, prostate and thyroid
cancers.
·
Amplification of the PIK3CA gene was commonly found in cervical (69%),
gastric (36%) and head and neck (32%) tumors; this amplification was also
commonly observed in different sub-types of lung cancers, including squamous
cell (53%), small cell (21%), adeno (13%) and non-small cell (12%) carcinomas.
In cancers of the ovaries, endometrium, breast, cervix, thyroid, astrocytes and
oesophagus the frequencies of amplified PIK3CA ranged from 6% to 12%.
·
Loss of heterozygosity of the PTEN-encoding gene occurred in 25% to 37% of
cancers of the skin, prostate, brain, stomach and breast. Loss of function
mutations were observed in cancers of the vulva (65%), endometrium (38%),
brain (21%), skin (17%), and prostate (14%).
Targeting PI3K also represents a rational therapeutic approach in cancers with overactive
PI3K signaling due to abnormal activity of an upstream receptor tyrosine kinase (RTK)
or G protein coupled receptors (GPCR) signaling pathway. Mutations in Ras-encoding
genes can also lead to overactive signaling through the PI3K pathway, and therefore
PI3K inhibition may also play a role in combination therapies aimed at shutting down
alternate signal transduction pathways such as the RAS/BRAF/MEK/ERK pathways.
Confidential
Page 20 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
Figure 1:
PI3K/AKT/mTOR Signaling Pathway Schema
(Extracted from: De Santis)
2.1.2.
SL-901
SL-901 is an orally bioavailable investigational anticancer drug aimed to treat patients
whose cancers harbor an overactive PI3K signaling. SL-901 can also be used in
combination with other anticancer therapies in patients whose tumor resistance
mechanisms to other therapies rely on signaling through the PI3K pathway, even when
PI3K is not mutated.
SL-901 is a PI3K inhibitor with a 50% inhibitory concentration (IC50) in the nanomolar
(nM) range against all 4 isoforms of PI3K; however, its IC50 against the α and d isoforms
is approximately one order of magnitude lower than against the β and g isoforms (the
SL-901 IC50 values against PI3Kα and PI3Kδ are 4.6 and 2.4 nM, respectively). SL-901
also inhibits PI3KC2β and deoxyribonucleic acid-dependent protein kinase (DNA-PK),
with an IC50 of 10 and 20 nM, respectively.
2.1.2.1.
Nonclinical Experience
Confidential
Page 21 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
2.1.2.2.
Clinical Experience
A Phase 1 first-in-human dose-escalation study of single-agent SL-901 administered QD
in 21-day cycles until development of unacceptable toxicity or progressive disease had
enrolled 13 patients in 4 cohorts (5 mg/day [N=4]; 10 mg/day [N=3]; 20 mg/day [N=3]
and 40 mg/day [N=3]), before the termination of the study by the prior Sponsor. While
only limited clinical data are available from this study, no dose-limiting toxicities (DLTs)
occurred at doses up to 40 mg/day. Furthermore, no deaths or SL-901-related serious
adverse events (SAEs) or ≥Grade 3 treatment-emergent adverse events (TEAEs) were
reported. No efficacy analysis was performed in the study.
2.2.
Rationale for Current Study and Risk/Benefit Assessment
SL-901 is an orally bioavailable adenosine triphosphate (ATP) homologue-type,
competitive, kinase inhibitor that competes with ATP for binding the ATP-binding
pocket of the catalytic subunit of PI3K enzymes. SL-901 induces cell cycle arrest in the
G1/0 phase of the cell cycle, and therefore is considered cytostatic rather than cytotoxic
or apoptosis-inducing. SL-901 IC50 against the α and d isoforms is approximately one
order of magnitude lower than against the β and g isoforms. The SL-901 target profile
partially overlaps with the profile of PI3Kα inhibitors that demonstrated clinical activity
in solid tumors and PI3Kδ inhibitors that demonstrated activity in lymphomas.
SL-901 may have a different therapeutic window than the currently available PI3K
inhibitors, as it is a more potent inhibitor of the PI3Kα and PI3Kδ isoforms than of the
PI3Kβ and PI3Kγ isoforms, and also inhibits PI3KC2β and DNA-PK with an IC50 of 10
and 20 nM, respectively, a profile that is different from those seen in currently available
PI3K inhibitors (see Table 3).
Confidential
Page 22 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
Table 3:
Summary of IC50 Values and Targets for Approved PI3K Inhibitors
and SL-901
Confidential
Page 23 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
3.
OBJECTIVES AND ENDPOINTS
This is a two-part study:
·
In Part 1a, escalating doses and 2 schedules (QD and twice daily [BID]) of
SL-901 administered daily in a 28-day treatment cycle will be evaluated in
patients with advanced solid tumors, to identify the maximum tolerated dose
(MTD) and determine the regimen for Part 1b.
·
In Part 1b, the safety of the selected administration regimen of SL-901 will be
assessed, as well as an initial assessment of clinical activity in patients with
advanced solid tumors known to have specific genetic alterations that may derive
benefit from treatment with a PI3K inhibitor.
The study objectives and endpoints are summarized in Table 4.
Table 4:
Study Objectives and Endpoints
OBJECTIVES
ENDPOINTS
Primary
·
To identify the MTD of SL-901.
·
 To identify an appropriate dosing
regimen for further investigation of
SL-901.
·
To characterize the PK profile of
SL-901.
·
To generate clinical safety data and
perform initial assessment of the
safety profile of SL-901.
·
Safety endpoints include identification of DLTs; rate
of TEAEs and SAEs; identification of abnormalities
in physical examination, vital signs, clinical
laboratory evaluations, and ECG findings.
·
PK endpoints include assessment of SL-901 plasma
concentration over time; assessment of any changes in
the PK properties of SL-901 between initial
administration and steady-state and between cycles of
treatment; explore the correlation between PK
parameters and toxicity.
Secondary
·
To characterize the PD of SL-901.
·
To assess preliminary clinical activity
of SL-901.
·
PD assessment of target phosphorylation will be
performed using a PI3K pathway triple assay (p-AKT,
p-p70S6K, and p-GSK3) in platelet-rich plasma
and/or tumor tissue and using immunofluorescence
for gamma H2AX in PBMCs.
·
Clinical activity endpoints include the rate of
objective response, rate of CR, DOR, PFS, and OS.
CR = complete response, DLT = dose-limiting toxicity, DOR = duration of response,
ECG = electrocardiogram, MTD = maximum tolerated dose, OS = overall survival,
p-AKT = phosphorylated-RAC-alpha serine/threonine-protein kinase (protein kinase B),
p-GSK3 = phosphorylated glycogen synthase kinase 3, p-p70S6K = phosphorylated p70S6 kinase, PBMC
= peripheral blood mononuclear cell, PD = pharmacodynamic(s), PFS = progression-free survival, PI3K =
phosphoinositide 3-kinase, PK = pharmacokinetic(s), SAE = serious adverse event,
TEAE = treatment-emergent adverse event
Confidential
Page 24 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
4.
STUDY DESIGN
4.1.
Overall Design and Operational Characteristics
This clinical study includes 2 parts:
1) Part 1a: an open-label, dose-escalation, and regimen-finding study to investigate the
safety, PK, and PD of SL-901 in patients with advanced solid tumors. In Part 1a,
adverse events (AEs) occurring during the first cycle of treatment will be considered
for the assessment of DLTs, with continued evaluation of AEs in subsequent
treatment cycles for further characterization of the safety of SL-901. This part will
follow a 3+3 dose-escalation design to determine the MTD of SL-901 when
administered on both a QD and BID schedule; single and multiple dose PK
assessments will be performed to characterize the exposure of SL-901. The
dose-escalation scheme to be followed is based on a modified Fibonacci sequence
schema, which also is commonly employed in Phase 1 dose-finding oncology studies
(Storer 1989).
2) Part 1b: Up to 4 expansion cohorts of patients with specific genetic alterations that
may derive benefit from treatment with a PI3K inhibitor will be treated SL-901 with
the dose regimen selected in Part 1a.
This clinical study will explore different dose levels and schedules of SL-901 given as a
single agent, therefore the term “regimen” is comprised of the unit dose administered and
the specified schedule of dosing in a given cohort.
4.1.1.
Dose-Escalation (Part 1a)
Part 1a employs a standard 3+3 design. The SL-901 starting dose will be 20 mg on both
the QD and BID schedule. The QD and BID schedules are planned to be tested in
parallel, with enrollment to the current cohort for each schedule conducted on an every
other patient basis. A treatment cycle is 28 days, with daily dosing throughout the cycle.
The planned dose levels are summarized in Table 5.
Table 5:
Planned SL-901 Dose Levels in Part 1a
Cohort
1
QD Dosing (mg/dose)
20
BID Dosing (mg/dose)
--
Total Daily Dose (mg/day)
20
QD = once daily, BID = twice daily
2
3
4
5
6
7
40
60
80
120
160
200
20
--
40
60
80
100
40
60
80
120
160
200
4.1.2.
Expansion Cohorts (Part 1b)
Up to 4 expansion cohorts at the MTD (or maximum tested dose if no MTD is identified,
or dose below the MTD if there is evidence suggesting a more favorable risk/benefit
profile) may be opened for enrollment with 6 to 12 patients in each cohort.
Although decisions regarding dose-escalation will be made based on review of data from
Part 1a, safety data will also be collected from all patients in Part 1b and reviewed
Confidential
Page 25 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
periodically by the Sponsor and Investigators. Any detected cumulative toxicity may
require later dose reductions or other action as appropriate, including further refinement
of the MTD.
4.1.3.
Justification for Study Design
Goals of Phase 1 oncology studies include estimation of the initial safety and tolerability
of a study drug, establishment of an MTD, determination of a recommended range of
doses for evaluation in future clinical studies (Ahn 1998, Gastontis 1992, International
Conference on Harmonisation 1997), and an initial characterization of the PK profile in
humans. The objectives of the current study are consistent with those typical of Phase 1
oncology studies.
Preliminary assessment of activity or potential therapeutic benefit may be a secondary
objective of Phase 1 studies (International Conference on Harmonisation 1997).
Consistent with this premise, a secondary objective is to evaluate the potential anti-tumor
activity of SL-901.
Confidential
Page 26 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
5.
STUDY POPULATION
5.1.
Inclusion Criteria
Patients meeting all the following criteria will be considered eligible for study entry:
1. 18 years old or older.
2. Population by study stage:
a. Part 1a: Patients with advanced, metastatic, and/or progressive solid tumors
for whom there is no effective standard therapy available.
b. Part 1b: Patients with histologically confirmed, advanced, metastatic,
unresectable, and/or progressive solid tumors for whom there is no effective
standard therapy available and their PI3K or DNA-PK pathway is deregulated
or their tumor genetic profile has been shown to correlate with sensitivity to
PI3K and/or DNA-PK inhibition based on clinical and preclinical experience.
Specific criteria will be determined based on ongoing experiments and will be
introduced in a future protocol amendment.
3. Evaluable or measurable disease.
4. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
5. Able to take oral medications.
6. If a woman of childbearing potential (WOCBP), the patient has a negative serum or
urine pregnancy test within 1 week before Cycle 1, Day 1 (C1D1). Refer to
Section 8.1.3 for further practical information about contraception.
7. The patient (either male or female) agrees to use acceptable contraceptive methods
for the duration of time in the study, and to continue to use acceptable contraceptive
methods for 1 month after the last dose of SL-901. Refer to Section 8.1.3 for further
practical information about contraception.
8. Able to provide written informed consent.
9. Willing to provide consent for biomarker analysis of existing paraffin-embedded
tumor samples.
5.2.
Exclusion Criteria
Patients meeting any of the following criteria will be excluded from the study:
1. Received an investigational anticancer drug within 4 weeks of the first planned
SL-901 dose.
2. Received major surgery, radiotherapy, or immunotherapy within 4 weeks of C1D1.
Localized palliative radiotherapy is permitted for symptom control.
3. Received chemotherapy regimens with delayed toxicity within 4 weeks (6 weeks for
prior nitrosourea or mitomycin C) of C1D1.
4. Received chemotherapy regimens given continuously or on a weekly basis which
have limited potential for delayed toxicity within 2 weeks of C1D1.
Confidential
Page 27 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
5. Clinically significant, unresolved toxicity from previous anticancer therapy ≥Grade 2
(except alopecia), as determined by the Investigator using the National Cancer
Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version
5.0.
6. Presence of active gastrointestinal disease or other condition that will interfere
significantly with the absorption, distribution, metabolism, or excretion of drugs.
7. Left ventricular ejection fraction <50%.
8. Corrected QT interval (based on Fridericia’s formula) >450 msec.
9. Type 1 or 2 diabetes mellitus requiring medication. (In Part 1b, patients with type 2
diabetes mellitus controlled by medication, as indicated by a glycated hemoglobin of
≤7.5% are eligible.)
10. Known active human immunodeficiency virus, hepatitis B, or hepatitis C infection.
11. Ongoing systemic bacterial, fungal, or viral infection.
12. History of interstitial pneumonitis.
13. Absolute neutrophil count (ANC) <1.5´109/L.
14. Hemoglobin <10 g/dL.
15. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5´ the upper
limit of normal (ULN).
16. Known hypersensitivity or allergy to the active ingredient or excipients of SL-901.
17. Breast-feeding females.
5.3.
Screen Failures
Screen failures are defined as patients who consent to participate in the clinical trial but
are not subsequently treated with SL-901. A minimal set of screen failure information is
required to ensure transparent reporting of screen failure patients, to meet the
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to
respond to queries from regulatory authorities. The required information includes
demography, screen failure details, eligibility criteria, and any SAE experienced.
Individuals who do not meet the criteria for participation in this trial (screen failure) may
be rescreened once. Rescreened patients will be assigned a new patient number (different
from the initial Screening number).
5.4.
Source of Patients
This will be a multi-center study. Each study center is required to obtain local
Institutional Review Board (IRB)/Ethics Committee (EC) and national regulatory
approval to conduct the study before enrollment of patients may commence. Patients
meeting the entrance criteria who are known or referred to the study center will be
eligible for enrollment.
Confidential
Page 28 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
6.
STUDY DRUG
6.1.
Study Drug Supply
All patients participating in this study will receive SL-901 as a single agent in an
open-label fashion. The Sponsor will supply SL-901 to all clinical sites.
6.2.
Study Drug Packaging and Storage
SL-901 capsules (20 mg and 60 mg) are packaged into 50-cc high-density polyethylene
(HDPE) bottles, 14 capsules per bottle. Bottles are capped with a child resistant tamper
evident polypropylene closure.
All bottles are labeled with a single panel clinical label containing pertinent information
for drug receipt and handling. Labeled bottles of 20 mg and 60 mg SL-901 capsules
received from the distributor should be stored in a locked cabinet accessible only to
appropriate study personnel.
SL-901 capsules are not to be stored above 25°C or frozen and are to be stored protected
from light. Keep out of reach of children. For additional information on study drug
handling including dispensing directions refer to the SL-901 Pharmacy Manual.
6.3.
Study Drug Accountability
Study drug will be dispensed to patients at scheduled study center visits on a per-cycle
basis. The Investigator or designee will maintain accurate records of receipt and
condition of the study drug, including dates of receipt and temperature monitoring. In
addition, records will be kept of the date dispensed, quantity dispensed, and the patient to
whom study drug was dispensed. Any reasons for departure from the protocol-specified
dispensing regimen must also be recorded in source documents and in the electronic case
report form (eCRF).
The Investigator or designee is responsible for the accountability of all used and unused
study drug containers and unused study drug. The site identification number and patient
identification number are to be recorded on each study drug accountability log. Each time
study personnel dispenses study drug for a patient, he or she is to record the date
dispensed, number of capsules of study drug dispensed, and his or her initials. When the
patient returns study drug, study personnel are to record the date returned, the number of
capsules returned or empty bottle(s), and any comments. Study personnel are to monitor
the inventory of clinical supplies and maintain a count of all used and unused containers.
The Clinical Research Associate (CRA) will review study drug accountability records
during routine monitoring visits. At the completion of the study, there will be a final
reconciliation of all study drug.
6.4.
SL-901 Dose and Administration
In both study parts, for the purposes of this study, a treatment cycle is considered to be
28 days, with daily dosing throughout the cycle.
Confidential
Page 29 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
Each SL-901 dose will be self-administered by the patient without food, either 2 hours
before or 2 hours after food. The dose regimen is dependent on the patient’s cohort
assignment (see Table 5), and SL-901 doses should be administered at approximately the
same time of day on each day of the cycle, if possible. For patients on the BID schedule,
doses should be taken morning and evening at approximately the same time each day of
the cycle, if possible.
On PK sample collection days, SL-901 should be administered at the study center and
should be administered at (approximately) the same time of day on each day of the cycle,
if possible. For patients on the BID schedule, start of PK collection must occur before the
first dose of the day.
In Part 1a, the SL-901 starting dose is 20 mg on a QD schedule and a total daily dose of
40 mg on a BID schedule, as specified in Table 5. The QD and BID schedules will be
tested in parallel, with enrollment to the current cohort for each schedule conducted on an
every other patient basis.
In Part 1b, the regimen of SL-901 will be based on the clinical experience in Part 1a.
6.4.1.
Dose-Escalation Scheme in Part 1a
Initially, up to 3 patients are to be enrolled in each cohort. After 3 patients complete C1
and have safety evaluations performed through C2D1, and if:
·
 None of these 3 patients experience a DLT in either dosing schedule, then
enrollment of the next cohort may commence.
·
1 of 3 patients within a cohort experiences a DLT, then up to 3 additional patients
are to be enrolled sequentially at that dose level in that dosing schedule. If none of
the additional 3 patients experience a DLT (i.e., 1 of 6 patients has a DLT), then
enrollment at the next scheduled dose may commence.
·
³2 patients within a cohort experience a DLT, then the DLT dose level will have
been reached and the previous lower dose level will be considered the MTD for
that dosing schedule.
Note that enrollment in the next dose cohort can begin only when the last patient enrolled
in the current dose cohort completes C1 and is assessed for DLT, provided that
<2 patients in the current dose cohort experienced a DLT.
Although decisions regarding dose-escalation will be made based on review of data from
C1, safety data will also be collected from all patients continuing treatment and this will
be reviewed periodically. Any detected cumulative toxicity may require later dose
reductions or other action as appropriate, including further refinement of the MTD.
Based on evaluation of the safety and tolerability data, it may be decided that escalation
to the next dose level should be more conservative than specified and that the next higher
dose will be an intermediate dose level.
An MTD will be identified for each dosing schedule.
Confidential
Page 30 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
6.4.2.
Dose-Limiting Toxicities
Patients are to receive at least 75% of the planned SL-901 doses in C1 and complete
study assessments through C2D1 to be eligible for DLT evaluation, unless discontinuing
due to DLT. Patients who receive <75% of the planned SL-901 doses in C1 and/or
discontinue before completing study assessments through C2D1 for reasons other than
DLT are to be replaced.
Toxicities are to be assessed by the Investigator according the NCI CTCAE, v5.0
(available at:
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Q
uick_Reference_5x7.pdf).
A DLT occurring during the Run-in PK period or in C1 is defined as any of the following
AEs for which there is a reasonable possibility that SL-901 caused the event. (Note that
while causality of an AE is to be determined by the Investigator, the Sponsor’s
assessment of causality can be used to override an Investigator’s designation of
‘unrelated’; however, the Sponsor’s assessment cannot be used to reverse an
Investigator’s designation of ‘related’ for the purpose of DLT determination.
·
Any ≥Grade 3 non-hematologic AEs, with the exceptions of:
- Grade 3 nausea, vomiting, diarrhea, constipation, fever, fatigue, or skin rash that
resolves to Grade <3 within 72 hours.
- Grade 3 laboratory abnormalities that are not associated with symptoms and
resolve to Grade 1 or baseline by C1D28 (unless otherwise specified).
·
Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with >Grade 1 bleeding or
requirement for platelet transfusion.
·
Grade 4 neutropenia lasting >5 days.
·
Febrile neutropenia (ANC <1´109/L with fever ≥38.5°C) of any duration.
·
 Persistent anemia (i.e., lasting >96 hours despite >2 red blood cell [RBC]
transfusions).
·
≥Grade 3 transaminase (AST/ ALT) elevation.
·
Any toxicity resulting in >7 held/skipped doses.
·
Any other significant toxicity considered by the Investigator or the Sponsor to be
dose-limiting (e.g., any toxicity considered at least possibly related to SL-901 that
results in patient withdrawal during C1).
In situations in which DLTs have occurred that would prevent further dose-escalation and
are severe but not life-threatening (i.e., persistent Grade 3 fever, malaise), re-evaluation
of specific dose cohorts may be considered with co-administration of appropriate
supportive care agents (e.g., corticosteroids, anti-depressants) concomitant with SL-901
therapy.
Confidential
Page 31 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
6.4.3.
Operational Characteristics of Dose-Escalation
All dose-escalation steps and schedule recommendations will be made by a review
committee, comprised of the study Investigators and Sponsor representatives, who will
review the available safety and other relevant data to inform the decision. Refer to the
Data Safety Review Charter (DSRC) for further details.
A sample size of at least 3 patients in each cohort, expanding to 6 patients in the event of
a marginal DLT rate (33%), is a conventional approach in dose-escalation studies of
investigational oncologic agents.
6.5.
Rationale for the Dose(s) Selected
Confidential
Page 32 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
6.6.
Dose Interruptions and Reductions
For patients that develop a clinically significant AE or unacceptable toxicity during
treatment, dosing should be interrupted.
·
If the toxicity resolves to the baseline level or Grade 1 within 7 days, then dosing
should resume at the same dose level (during C2 and beyond, dose reduction may
also be considered in consultation with the Sponsor).
·
If the toxicity resolves to the baseline level or Grade 1 within 8 to 14 days, then
dosing in C2 and beyond may be resumed at a reduced dose after consultation
with the Sponsor.
·
If the toxicity fails to resolve to baseline or Grade 1 within 14 days, then the
patient should be discontinued from treatment permanently.
Specific management of unusual non-autoimmune and non-infectious toxicities known to
be associated with PI3K inhibitors are summarized in Table 6 (Greenwell 2017).
Table 6:
Management of Unusual Non-Autoimmune and Non-Infectious
Toxicities
Observe
Hold
Drug
Hypertension
BP ≥
140/90 mmHg
BP ≥
200/110 mmHg
Hyperglycemia
FG ULN-160 mg/dL
FG >160 mg/dL or
NFG ≥200 mg/dL
Confusion
Mild
disorientation
Limit ADL
Anxiety/
depression
Mild symptoms
Limit ADL
Rash
≤30% BSA
>30% BSA
Abbreviations: ADL = activities of daily living, BP = blood pressure, BSA = body surface area, FG = fasting glucose,
NFG = non fasting glucose, ULN = upper limit of normal
6.6.1.
Intra-Patient Dose-Escalation
Intra-patient dose escalation to the MTD may be considered for patients who, at the time
the MTD is determined, have experienced a confirmed objective response or stable
disease for at least 4 treatment cycles with SL-901; AND have not experienced any
≥Grade 3 toxicity that was considered by the Investigator to be related to SL-901; AND
do not exhibit any evidence of cumulative toxicity that can be considered related to
SL-901.
Confidential
Page 33 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
7.
STUDY INTERVENTION DISCONTINUATION AND
PATIENT DISCONTINUATION/WITHDRAWAL
7.1.
Patient Withdrawal and Replacement
Patients may be withdrawn from the study for any of the following reasons:
·
Patient, Investigator, or Sponsor request.
·
Protocol violation.
·
Non-compliance to protocol.
·
AE.
·
Pregnancy.
·
Progression of disease that, in the opinion of the Investigator, precludes further
study treatment.
·
Lost to follow-up.
The reason for study withdrawal is to be documented in the patient’s source documents
and eCRF.
See Section 6.4.2 for replacement of patients that discontinue treatment during C1.
Patients that discontinue treatment after C1, for any reason and at any stage, will not be
replaced.
7.2.
Dose Modifications
In Part 1a, dose modifications are not allowed in the PK Run-in Period and C1.
7.3.
Treatment Discontinuation
Study drug may be discontinued for any of the following reasons:
·
Progression of disease that, in the opinion of the Investigator, precludes further
study treatment. After consultation with the Sponsor, SL-901 may be continued
for a patient who has met the criteria for progressive disease but in the
Investigator’s opinion, continues to derive benefit from study treatment.
·
Occurrence of an unacceptable AE, including DLT.
·
Pregnancy.
·
SL-901 interruption due to study drug-related toxicity for >1 cycle
(i.e., >28 days). Interruptions or delays >28 days for reasons other than AEs
and/or in the setting of sustained disease control may be acceptable and are to be
discussed with the Medical Monitor.
·
Patient requires use of a prohibited concomitant medication or therapy.
·
General or specific changes in the patient’s condition unacceptable for further
treatment within the study parameters, in the judgment of the Investigator.
·
Non-compliance.
Confidential
Page 34 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
·
Lost to follow-up.
·
Patient withdrawal of consent.
·
Sponsor request.
·
Other.
All study procedures outlined for the End-of-Treatment (EOT) visit should be performed
30 days (±3 days) after the last study drug dose.
In Part 1a, patients who receive <75% of the planned SL-901 doses in C1 and/or
discontinue from the study before completing study assessments through C2D1 for
reasons other than DLT are to be replaced.
7.4.
Lost to Follow-Up
A patient will be considered lost to follow-up if they are unable to be contacted by the
study site staff.
The following actions must be taken if a patient fails to return to the clinic for a required
study visit:
·
 The site will attempt to contact the patient and reschedule the missed visit within
7 days of the originally planned study visit and counsel the patient on the
importance of maintaining the assigned visit schedule and ascertain if the patient
wishes to and/or should continue in the study.
·
Before a patient is deemed lost to follow-up, the Investigator or designee will
make every effort to regain contact with the patient. These contact attempts
should be documented in the source documents, and at least three documented
contacts are needed to consider a patient lost to follow-up.
Should the patient continue to be unreachable, he or she will be considered to have
withdrawn from the study with a primary reason of lost to follow-up.
Confidential
Page 35 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
8.
STUDY ASSESSMENTS
8.1.
Screening Assessments
Screening assessments are performed subsequent to the patient providing an informed
consent and before the first administration of SL-901 at the Run-in PK sampling day, see
Section 8.7. These assessments are to be performed within 28 days of the Run-in PK
sampling day (during Screening), unless otherwise specified.
8.1.1.
Demographic Data, Medical History, ECOG Performance Status, and
Cancer History
Patient demographics, including age, sex, race, and ethnicity, are to be documented
during Screening.
The medical history is to include cancer history, including the patient’s primary tumor
type, current disease stage, date of and disease stage at diagnosis, and all previous
treatments, including systemic therapy, radiation therapy, and surgeries, as well as
response to such treatment, when available.
A complete medical history is to be documented during Screening. The medical history
should include a minimum of the prior 2 years, whenever possible, with information for
longer durations, when feasible. ECOG performance status also is to be documented
during Screening.
8.1.2.
Prior Medications
All medications taken within 28 days before the initial Screening visit through the EOT
visit, including nonprescription medications, dietary supplements and the specific
dose/schedule of any systemic corticosteroid agents, should be recorded.
8.1.3.
Contraception, Pregnancy and Pregnancy Testing
From the time of provision of written informed consent throughout the duration of the
study, and for 1 month after last dose of SL-901, female subjects of childbearing potential
must use a highly effective method of contraception. This also applies to any female
partners of male study participants.
Serum or urine samples for beta-human chorionic gonadotropin pregnancy testing are to
be collected from WOCBP during Screening to be eligible for participation in the study.
A pregnancy test must be collected during the Run-in visit and this pregnancy test result
must be reviewed and determined to be negative before administration of the first study
drug dose at the Run-in PK sampling visit. Pregnancy testing is to be repeated monthly at
the Day 1 visit of each cycle beginning with Cycle 2 and again after the last SL-901 dose,
(at a time after the end of the relevant period of exposure). Pregnancy testing during the
study should additionally occur at any time pregnancy is suspected.
A WOCBP is defined as any female who has experienced menarche and who has not
undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or
bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea
≥12 consecutive months; or women on hormone replacement therapy with documented
serum follicle-stimulating hormone level ≥35 mIU/mL).
Confidential
Page 36 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
A highly effective method of contraception is defined as one that has no higher than a 1%
failure rate. In this study, the only highly effective methods of contraception are:
·
Combined (estrogen and progestogen containing) hormonal contraception
associated with inhibition of ovulation, including oral, intravaginal, and
transdermal formulations.
·
 Progestogen-only hormonal contraception associated with inhibition of ovulation,
including oral, injectable, and implantable formulations.
·
Intrauterine device.
·
Intrauterine hormone-releasing system.
·
Bilateral tubal occlusion.
·
Vasectomized partner, provided that partner is the sole sexual partner of a study
patient of child-bearing potential and that the vasectomized partner has received
medical assessment of the surgical success.
·
Sexual abstinence, when this is in line with the preferred and usual lifestyle of the
study patient. (Periodic abstinence [.eg, calendar, ovulation, symptothermal, post
ovulation methods for the female partner] and withdrawal are not acceptable
methods of contraception.)
Male patients in this study must consent to use a condom throughout the duration of the
study, and for 1 month after last dose of SL-901, and their female partners who are of
child-bearing potential must use highly effective contraception, as listed above.
Prior to study enrollment, WOCBP must be advised of the importance of avoiding
pregnancy during study participation and the potential risk factors for an unintentional
pregnancy. This information will be included in the informed consent form (ICF) that
must be signed by the patient. In addition, all WOCBP or fertile men with partners of
childbearing potential should be instructed to contact the Investigator immediately if they
suspect they or their partner might be pregnant (e.g., missed or late menstrual period) at
any time during study participation.
Patients with a positive pregnancy test result during Screening are not eligible for study
participation. Patients with a positive result at any time after the start of study drug
administration are to have study drug permanently discontinued. Refer to Section 8.6 for
details regarding management of any pregnancies during the study.
8.1.4.
Physical Examination
A complete physical examination, including measurement of height, is to be performed
during Screening, on Day 1 of each cycle and at End of Treatment. Physical examinations
are to be conducted by a physician or health professional licensed to perform physical
Confidential
Page 37 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
examinations and designated by the Investigator. The complete physical examinations
should include assessment of the following:
·
General appearance
·
Eyes, ears, nose, and throat
·
Head and neck
·
Chest and lungs
·
Cardiovascular system
·
Gastrointestinal system (abdomen)
·
Musculoskeletal system
·
Lymphatic system
·
Dermatologic
·
Neurological (including questioning regarding whether the patient is experiencing
any numbness and/or pain as well as light touch, sharp touch [skin prick], and
temperature, position [proprioception], and vibration sensation testing. Additional
neurological assessments are to be performed as appropriate for the patient’s
condition, at the Investigator’s discretion.)
·
Psychiatric
·
Extremities
Symptom-directed (i.e., abbreviated) physical examinations are to be conducted at all
other study visits.
Abnormal physical examination findings that are considered by the Investigator to be
clinically significant during Screening and before initial dosing are to be reported as part
of the patient’s medical history. Abnormal, clinically significant examination findings
following initiation of dosing are to be reported as AEs, if the finding represents
worsening from baseline or new onset.
8.2.
Adverse Events and Serious Adverse Events
8.2.1.
Definitions
Adverse Event (AE)
An AE is any untoward medical occurrence in a study patient who is administered a
medicinal product (study drug), regardless whether or not considered drug-related. An
AE can therefore be any unfavorable and unintended sign including abnormal
laboratory/examination findings, symptoms, or disease(s) temporally associated with the
use of study drug, whether or not related to study drug. An AE can arise from any use of
the drug (e.g., off-label use, use in combination with another drug) and from any route of
administration, formulation, or dose, including an overdose.
Serious Adverse Event (SAE)
Confidential
Page 38 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
An AE is considered serious (i.e., an SAE) if, in the view of either the Investigator or
Sponsor, it meets any of the following criteria:
·
Results in death.
·
Is life-threatening. Life-threatening means that the patient was at immediate risk
of death from the reaction as it occurred (i.e., it does not include a reaction which
hypothetically might have caused death had it occurred in a more severe form).
·
Requires in-patient hospitalization or prolongation of existing hospitalization.
Hospitalization admissions and/or surgical operations scheduled to occur during
the study period, but planned before study entry are not considered adverse events
if the illness or disease existed before the patient was enrolled in the study,
provided that it did not deteriorate in an unexpected manner during the study (e.g.,
surgery performed earlier than planned).
·
Results in persistent or significant disability/incapacity or substantial disruption of
the ability to conduct normal life functions.
·
Results in a congenital anomaly/birth defect.
Important Medical Event (IME)
An important medical event (IME) that may not result in death, be life-threatening, or
require hospitalization may be considered serious when, based upon appropriate medical
judgment, it may jeopardize the patient or subject and may require medical or surgical
intervention to prevent one of the outcomes listed in the definitions for SAEs.
Note: The onset date of an SAE is defined as the date on which the event initially met
serious criteria (e.g., the date of admission to a hospital). The end date is the date on
which the event no longer met serious criteria (e.g., the date the patient was discharged
from a hospital).
8.2.2.
Adverse Event Assessment and Reporting
All serious and non-SAEs will be recorded in the study’s clinical database:
·
 AEs – from the day of first exposure to SL-901 through 30 days after the last dose
of SL-901.
·
SAEs – from the day of informed consent signature by the patient through 30 days
after the last dose of SL-901.
This includes AEs that patients report spontaneously, those observed by the Investigator,
and those elicited by the Investigator during scheduled study center visits.
All AEs entered into the clinical database are to contain the following details regarding
the AE: diagnosis/AE term (in case diagnosis is unknown), start/stop date, intensity,
relationship to study drug, action taken with study drug due to the event, whether
intervention was required, outcome, and whether the event is classified as serious. The
Investigator must continue to follow all SAEs and non-serious AEs until resolution, or
until the Investigator assesses them as chronic or stable.
Each AE is to be assessed by the Investigator for the following categories.
Confidential
Page 39 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
Serious/Non-Serious
AEs that meet the criteria specified in Section 8.2.1 are to be considered serious.
Relationship to Study Drug
The relationship of each AE to study drug is to be assessed by the Investigator according
to the following criteria:
·
Related: A temporal relationship exists between the event onset and
administration of SL-901. It cannot be readily explained by the patient’s clinical
state, intercurrent illness, or concomitant therapies. In case of cessation or
reduction of the dose, the event abates or resolves and reappears upon
rechallenge. This includes events that are considered possibly, probably, or
definitely related to SL-901.
·
Not Related: Evidence exists that the AE has an etiology other than the study
drug (e.g., pre-existing condition, underlying disease, intercurrent illness, or
concomitant medication). This includes events that are considered probably not or
not related to SL-901. It should be emphasized that ineffective study drug
treatment should not be considered as causally related in the context of AE
reporting (in other words, disease progression is not considered an AE; however
some sequelae of disease progression may be reported as AEs and should
generally be reported as AEs not related to investigational therapy).
An Investigator who is qualified in medicine must make the determination of relationship
to the investigational product for each AE. The Investigator should decide whether, in his
or her medical judgment, there is a reasonable possibility that the event may have been
caused by the investigational product. The following factors for study drug relationship
should be referenced when making a determination of “related” or “not related.”
·
The temporal sequence from study drug administration: The event should occur
after the study drug is given. The length of time from study drug exposure to
event should be evaluated in the clinical context of the event.
·
Underlying, concomitant, intercurrent diseases: Each report should be evaluated
in the context of the natural history and course of the disease being treated and
any other disease the patient may have.
·
Concomitant medication: The other medications the patient is taking or the
treatment the patient receives should be examined to determine whether any of
them might be recognized to cause the event in question.
·
Known response pattern for this class of study drug: Clinical and/or preclinical
data may indicate whether a particular response is likely to be a class effect.
·
Exposure to physical and/or mental stresses: The exposure to stress might induce
adverse changes in the recipient and provide a logical and better explanation for
the event.
Confidential
Page 40 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
·
The pharmacology and PK of the study drug: the known pharmacologic
properties (absorption, distribution, metabolism, and excretion) of the study drug
should be considered.
Intensity
The intensity of each AE is to be assessed by the Investigator according to the NCI
CTCAE Version 5.0 (available at:
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Q
uick_Reference_5x7.pdf). If the AE is not included in the NCI CTCAE, then the
Investigator is to determine the intensity of the AE according to the following criteria:
Mild (Grade 1): AE that disappears or is easily tolerated on continuation of study drug.
Moderate (Grade 2): AE that disappears or is easily tolerated on continuation of study
drug.
Severe (Grade 3): AE sufficiently discomforting to cause interference with usual work
activities.
Life-Threatening (Grade 4): AE that is potentially life-threatening.
Death (Grade 5): Results in the patient’s death.
A severe event is not necessarily a serious event. For example, a headache may be severe
(interferes significantly with patient’s usual function) but would not be classified as
serious unless it met one of the criteria for serious events as previously defined.
8.2.3.
Reporting Serious Adverse Events
The Investigator must report all SAEs within 24 hours of discovery via e-mail to the
Sponsor’s Safety Vendor at the following e-mail:
STML-901-0119_PV@tigermed.net
The completed SAE report is to be sent within 24 hours of discovering the event. The
initial report should include at least the following information:
·
Patient’s study identification number
·
Date, description and time (if available) of the event
·
Criterion for seriousness
·
Preliminary assignment of relationship to study drug
The Safety Vendor will confirm receipt of the report. The Sponsor will review the report
and determine if any follow-up queries are needed for the study site. The Investigator will
be contacted for follow-up information regarding the SAE, as appropriate. Follow-up
reports should be sent in a timely fashion as information becomes available.
SAEs that are considered at least possibly related to the investigational product and
unexpected (i.e., Suspected Unexpected Serious Adverse Reactions [SUSARs]), will be
Confidential
Page 41 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
reported to the applicable regulatory authorities and IRB/EC by the Sponsor or Sponsor’s
designee as required by applicable local regulations. Per regulation, any fatal or life-
threatening SUSAR will be reported to the regulatory authorities and IRB/EC within 7
calendar days, and additional information within an additional 8 calendar days. The
Sponsor or Sponsor’s designee is required to submit any other SUSAR to the regulatory
authorities and IRBs/ECs within 15 calendar days of notification. The Sponsor or its
designee is also responsible for notifying the investigational sites of all expedited SAEs.
The Investigator must keep copies of all expedited SAE information including
correspondence with the Sponsor on file.
8.2.4.
Special Cases: Overdose and Pregnancy
Overdose is defined as an occurrence in which more drug is administered than the
intended amount. Signs and symptoms considered to be a result of an overdose should be
reported as AEs. Overdoses will not be considered SAEs unless the outcome of the
overdose meets seriousness criteria (see Section 8.2.1).
Pregnancies or pregnancies of partners by study patients occurring while the patient is
receiving SL-901 or within 30 days after the patient’s last dose of SL-901 will not be
considered serious, but are to be reported using the same procedures as for SAEs
described in Section 8.2.1 as IMEs.
8.2.5.
Protocol Deviations Due to an Emergency or Adverse Event
Generally, deviations from the protocol require pre-approval by the Sponsor on a
case-by-case basis. In medical emergency situations, the Investigator or other physician
in attendance may exercise their medical judgment without prior approval but will need
to subsequently report the deviation to the Sponsor.
8.3.
Laboratory Assessments
Laboratory abnormalities that are considered by the Investigator to be clinically
significant for a particular patient during Screening and before the first study drug dose
are to be reported as part of the patient’s medical history. After the first study drug dose,
any clinically significant (as determined by the Investigator) worsening in laboratory
assessments or other clinical findings should be considered an AE.
Blood samples for hematology and clinical chemistries are to be collected at the time
points designated in Table 1 and Table 2.
The laboratory parameters that will be measured during the study are summarized in
Table 7.
Confidential
Page 42 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
Table 7:
Hematology
Chemistry
Coagulation
Clinical Laboratory Parameters to be Measured During the Study
Hematocrit
Hemoglobin
Platelet count
White blood cell count with differential
Alanine aminotransferase (ALT)
Albumin
Alkaline phosphatase
Aspartate aminotransferase (AST)
Bilirubin
Bicarbonate
Blood urea nitrogen
Calcium
Chloride
Creatinine
Glucose
Lactate dehydrogenase
Magnesium
Phosphate
Potassium
Sodium
Total protein
Uric acid
Prothrombin time or international normalized ratio
8.4.
Weight and Vital Signs
Vital signs, including temperature, heart rate, respiration rate, blood pressure (BP), and
weight are to be measured. Vital signs should be measured after the patient has been
sitting for 3 to 5 minutes.
8.5.
Concurrent Medications
All prescription and non-prescription medications and therapies, including pharmacologic
doses of vitamins, herbal medicines, or other non-traditional medicines, taken from
28 days before the first dose of SL-901 through the EOT visit. On PK sample collection
days, both the date and time of concomitant medications and therapies should be
recorded.
8.5.1.
Prohibited Concurrent Medications
The following medications are prohibited during the study:
·
Any investigational agent or device other than SL-901, including agents that are
commercially available for indications other than the patient’s solid tumor that are
under investigation for the treatment of solid tumors.
·
Any anti-neoplastic treatment with activity against solid tumors other than SL-901.
Confidential
Page 43 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
8.5.2.
Permitted Concurrent Medications
Medications and treatments other than those specified in Section 8.5.1, including
palliative and supportive care for disease-related symptoms (e.g., appetite stimulants,
stimulants [modafinil], anti-cachexia therapy [fish-oil supplements], anti-depressants,
opiate and non-opiate analgesics, antibiotics, selective use of corticosteroids, and, as
indicated below, anti-emetic and anti-diarrheal agents and hematopoietic growth factors),
are permitted during the study. In case of hyperglycemia grade 3 or higher, treatment
with Metformin is permitted.
Patients should be closely monitored, and treatment is to be instituted for disease-related
symptoms, as appropriate.
8.5.3.
Additional Important Considerations
Clinical drug-drug interaction studies with SL-901 have not been performed.
Concomitant therapy with drugs that are strong inhibitors or inducers of CYP3A and
induce CYP2B6 (e.g., clarithromycin, itraconazole, phenytoin, rifampicin), may cause
SL-901 toxicity or lack of efficacy. In addition, drugs that are substrates of CYP3A (e.g.,
drugs include amlodipine, amitriptyline, and carbamazepine) may reach toxic levels of
exposure due to inhibition by SL-901, and therefore caution with use of such drugs is
advised.
8.6.
Pregnancy
Pregnancies occurring in the patient or patient’s partner while the patient is receiving
study drug or within 30 days after the patient’s last dose of study drug will not be
considered serious, but are to be reported as IMEs using the same procedures as for SAEs
described in Section 8.2.1.
Study drug must be discontinued immediately in the event of a pregnancy. The patient
should be referred to an obstetrician/gynecologist experienced in reproductive toxicity for
further evaluation and counseling.
The Investigator will follow the patient until completion of the pregnancy and must
notify the Sponsor of the outcome. The Investigator will provide this information as a
follow-up to the initial report.
If the outcome of the pregnancy meets the criteria for immediate classification as an SAE
(i.e., spontaneous abortion [any congenital anomaly detected in an aborted fetus is to be
documented], stillbirth, neonatal death, or congenital anomaly), then the Investigator
should report it as such. Furthermore, all neonatal deaths that occur within 30 days of
birth should be reported, without regard to causality, as SAEs. In addition, any infant
death after 30 days that the Investigator suspects is related to the in utero exposure to the
study drug should also be reported.
8.7.
Tumor Assessments
Tumor assessment by will occur at Screening (for identification of baseline disease) and
after every 2 cycles of treatment thereafter. Response will be evaluated using Response
Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Eisenhauer 2009).
Confidential
Page 44 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
After completion of the EOT visit, patients will then be followed every 90 days for
survival status for 12 months. The survival follow-up may be by telephone contact. If the
patient discontinued study drug for reasons other than progressive disease, disease
assessments should continue to be performed on an every 8-week basis (±1 week)
through 6 months after the first study drug dose and then on an every 90-day basis or
until, in the judgment of the Investigator, there is evidence of relapsed or progressive
disease.
8.8.
Pharmacokinetics
See Table 8 for the PK assessment schedule.
Confidential
Page 45 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
8.9.
Electrocardiogram
Twelve-lead ECGs will be performed 5 to 10 minutes before the PK sample is collected
and analyzed locally in triplicate over 5 minutes (±5 minutes) contemporaneously with
selected PK sampling time points, as indicated in Table 8.
Table 8:
Time Points for Pharmacokinetic and Electrocardiogram Assessments
Steady State Sampling
and ECGs
Run-in Serial PK
(C1D8; C1D22;
Sampling and ECGs
C2D1; C2D8; C2D15;
Serial PK Sampling
(3-7 days before               C2D22; Cycles 3 and                   and ECGs
C1D1;
beyond D1, D15
(C1D15
Part 1a only)
Part 1a and Part 1b)
Part 1a and Part 1b)
Timepoint
PK
ECG1                       PK
ECG1                       PK
ECG1
Predose                                  X                    X                    X                    X                    X                    X
60 minutes postdose              X                    X                    --                    --                    X                    X
2 hours postdose
X
X
--
--
X
X
4 hours postdose
X
X
--
--
X
--
6 hours postdose
X
--
--
--
X
--
8 hours postdose
X
--
--
--
X
--
10 hours postdose
X
--
--
--
X
--
12 hours postdose
X
--
--
--
X
--
24 hours postdose
X
X
--
--
X
X
48 hours postdose
X
X
--
--
--
--
72 hours postdose
X
X
--
--
--
--
C = cycle, D = day, ECG = electrocardiogram, PK = pharmacokinetic
1.
ECG should be performed as triplicates and at least 5-10 minutes before the PK sample is collected.
8.10.
Pharmacodynamics
Confidential
Page 46 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
9.
STATISTICAL CONSIDERATIONS
9.1.
Statistical Basis for Sample Size
No formal sample size calculation is required in this Phase 1 dose-escalation and dose
expansion study. For each dosing schedule, 3 to 6 patients are to be enrolled in each dose-
escalation cohort in Part 1a. Up to 60 patients in total are to be enrolled in the dose-
escalation cohorts.
The total number of patients to be enrolled is dependent upon the observed safety profile,
which will determine the number of patients per dose cohort, as well as the number of
dose-escalations required to achieve the MTD.
A sample size of at least 3 patients in each cohort, expanding to 6 patients in the event of
a marginal DLT rate (33%), is a conventional approach in dose-escalation studies of
investigational oncologic agents.
Six to 12 patients in each expansion cohort (up to 4 cohorts) are to be enrolled in Part 1b.
9.2.
Populations for Analysis
The intent-to-treat (ITT) principal will be followed for the safety and efficacy
populations. This is defined as all patients enrolled into the study and who received any
amount of SL-901.
As warranted by the data, efficacy also may be assessed in a per-protocol population,
defined as all patients who receive at least 1 cycle of treatment, have at least
1 post-baseline efficacy assessment, and have no major protocol violations, as defined by
the Sponsor.
PK analyses will be performed on the PK population, defined as all patients who receive
any amount of SL-901 and have sufficient data for PK analysis.
9.3.
Statistical Analysis Plan
9.3.1.
Patient Disposition
Data tabulations will summarize the number of patients:
·
Enrolled
·
At least 1 SL-901 dose received
·
Evaluable for safety and efficacy
·
Protocol violations
·
 Withdrawn from study due to:
- AE
- Investigator request
- Withdrew consent
- Lost to Follow-up
- Other reasons
Confidential
Page 47 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
9.3.2.
Demographic and Baseline Characteristics
Demographic and baseline characteristics of patients will be summarized using
descriptive statistics, including:
·
Age
·
Sex
·
Race
·
Ethnicity
·
Baseline ECOG performance status
·
Primary diagnosis
·
Disease stage at diagnosis and Baseline
·
Prior therapies, including systemic therapies, radiation, and surgeries
·
Other baseline characteristics
9.3.3.
Concurrent Medications
The number and proportion of patients in the safety analysis set using different
concomitant medications will be tabulated and summarized by World Health
Organization Drug anatomical, therapeutic, chemical class and preferred term (PT). All
concomitant medications administered will be presented in a data listing.
9.3.4.
Safety Analyses
Safety analysis will be performed on the ITT population. Safety analyses in addition to
those described in the following subsections may be performed at any time without
prejudice, in order to most clearly enumerate rates of toxicities and to define further the
safety profile of SL-901.
Treatment-Emergent Adverse Events
·
 AEs will be considered treatment-emergent (i.e., TEAEs) if they start on or after
the time of the first dose of SL-901 and up to 30 days after the last dose of
SL-901.
·
TEAEs will be summarized by Medical Dictionary for Regulatory Activities
(MedDRA™), Version 22 (or higher), system organ class (SOC) and PT. The
severity of AEs will also be summarized by NCI CTCAE, Version 5.0 (or higher).
·
Non-treatment-emergent AEs will be included in the patient listings and flagged
as such but will not be included in the summary tables.
·
Where an AE date is partial or missing, and it is unclear whether the AE is
treatment-emergent, the AE will be assumed to be treatment-emergent.
Confidential
Page 48 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
Summary of TEAEs
The number and percentage of patients who experience TEAEs will be summarized
overall by SOC and PT and will also be summarized based on severity and causality.
Descriptive analysis of AEs will include incidence of TEAEs and SAEs grouped by:
·
SOC and PT
·
SOC, PT and severity
·
SOC, PT and causality
·
SOC and PT leading to discontinuation from the study
·
SOC and PT for events ≥Grade 3
·
SOC and PT leading to death
Individual listings of all AEs will also be provided.
9.3.4.1.
Laboratory Parameters
Laboratory results (hematology, chemistry and coagulation parameters) will be graded
according to NCI CTCAE, Version 5.0 (or higher). Laboratory results not corresponding
to an NCI CTCAE term will not be graded. Incidences of laboratory abnormalities will be
summarized with descriptive statistics.
Shift tables will generated to display changes from baseline to the worst value on study
and last value on study using values provided by the local laboratory.
All laboratory data will be included in listings and abnormal results will be flagged.
9.3.4.2.
Vital Signs and Body Weight
Changes in vital sign parameters (including systolic and diastolic blood pressure and
heart rate) and body weight will be summarized over time, and any abnormal values will
be tabulated.
9.3.4.3.
ECOG Performance Status
ECOG performance status will be summarized by cycle; ECOG performance status will
be presented in data listing format.
9.3.4.4.
Physical Examination
The analysis of physical examination will focus on patients who develop abnormalities
post-baseline or whose evaluations worsen after baseline. Frequency tables will display
the number and frequency of patients with any abnormalities. The results of abnormal
physical examinations will also be listed.
9.3.5.
Efficacy Analyses
·
Response evaluation is based upon the Investigator’s determination of response
using RECIST v1.1 (Eisenhauer 2009). A response is defined as instance of a
patient exhibiting a confirmed complete response (CR) or partial response (PR).
Confidential
Page 49 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
·
Objective response rate (ORR) is defined as the number of patients exhibiting
response divided by the number of patients qualified for tumor response analysis.
·
Progression-free survival (PFS) is defined as the time from the first study drug
dose to the first date of objectively determined disease progression or death from
any cause. For patients who are still alive at the time of analysis and without
evidence of tumor progression, PFS will be censored at the date of the most recent
objective progression-free observation. For patients who receive subsequent
anticancer therapy before objective disease progression or death, PFS will be
censored at the date of the last objective progression-free observation before the
date of subsequent therapy.
·
 Duration of response (DOR) is defined as the time from the date when the
measurement criteria are met for CR or PR (whichever status is recorded first)
until the date of first observation of objective disease progression. Duration of
response will be censored at the date of the last objective progression-free disease
assessment for patients who respond to treatment and die without progressive
disease (excluding death from study disease). For responding patients not known
to have died at the time of the data analysis and who do not have progressive
disease, duration of response will be censored at the last progression-free
assessment date. The disease control rate (DCR; CR + PR + stable disease) will
be similarly analyzed.
For responding patients who receive subsequent anticancer therapy (after
discontinuation from all study treatment) before disease progression, duration of
response will be censored at the date of last progression-free assessment before
the initiation of post-discontinuation anticancer therapy.
·
 Duration of CR (DOCR) is defined as the time from the date when the
measurement criteria are met for CR until the date of first observation of objective
disease progression.
·
 Overall survival (OS) is defined as the time from the first study drug dose to the
date of death from any cause. For patients who are still alive at the time of the
analysis, OS time will be censored on the date of the patient’s last contact.
9.3.6.
Pharmacokinetic Analysis
Confidential
Page 50 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
9.3.7.
Electrocardiogram Analysis
The proportions of patients with treatment-emergent clinically significant ECG
abnormalities will be tabulated, and changes in ECG findings will be presented in data
listing format. If warranted, categorical analyses of QTc interval data will be provided for
the number and percentage of patients meeting or exceeding the following threshold
values:
·
Absolute QTc interval prolongation: QTc interval >450 ms, >480 ms, and
>500 ms
·
Change from Baseline in QTc interval: QTc interval increases >30 ms and >60 ms
9.3.8.          Pharmacodynamic Analysis
PD analyses will be described in a separate Statistical Analysis Plan.
9.4.
Changes to the Planned Statistical Methods
Changes to the planned statistical methods will be documented in the clinical study
report.
Confidential
Page 51 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
10.
10.1.
10.1.1.
SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS
Ethical, Legal, and Administrative Considerations
Informed Consent
Written informed consent in compliance with 21 Code of Federal Regulations (CFR) § 50
and/or International Council for Harmonisation (ICH) will be obtained from each patient
before undergoing any protocol-specific tests or procedures that are not part of routine
care.
The Sponsor will provide an ICF template to the Investigator for use in developing a
study center-specific ICF. Prior to submission of the study center-specific ICF to the
IRB/EC, the study center-specific ICF must be reviewed and approved by the Sponsor.
Any changes requested by the IRB/EC must also be approved by the Sponsor. The final
IRB/EC-approved ICF must be provided to the Sponsor. Revisions to the ICF required
during the study must be approved by the Sponsor, and a copy of the revised ICF
provided to the Sponsor.
Before recruitment and enrollment, each prospective patient (or legal guardian) will be
given a full explanation of the study and be allowed to read the ICF. After the
Investigator or designee is assured that the patient/legal guardian understands the
commitments of participating in the study, the patient/legal guardian will be asked to sign
and date the ICF.
A copy of the fully signed and dated ICF will be given to the patient. The original will be
maintained in the patient’s medical record at the study center.
10.1.2.
Study Discontinuation and Closure
If the Sponsor or Investigator discovers conditions arising during the study that suggest
the study should be halted, then this can happen only after appropriate consultation
between the Sponsor and the Investigator. Conditions that may warrant study termination
include, but are not limited to:
·
The discovery of any unexpected, significant, or unacceptable risk to the patients
enrolled in the study.
·
Failure of the Investigator to enter patients at an acceptable rate.
·
Insufficient adherence to the protocol requirements.
·
A decision on the part of the Sponsor to suspend or discontinue development of
SL-901.
10.1.3.
Confidentiality and Privacy
All study findings and documents will be regarded as confidential. The Investigator and
other study personnel must not disclose such information without prior written approval
from the Sponsor.
Confidential
Page 52 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
Patient confidentiality will be strictly maintained to the extent possible under the law.
Patient names must not be disclosed. Patients will be identified on the eCRFs and other
documents submitted to the Sponsor or its designated representative, by their initials
and/or birth date and/or assigned patient number. Documents that identify the patient
(e.g., the signed ICF) should not be submitted to and/or or its designated representative,
and must be maintained in confidence by the Investigator.
10.1.4.
Future Use of Stored Specimens and Data
Data collected for this study will be analyzed and stored by the Sponsor or designee.
After the study is completed, the de-identified, archived data will be transmitted to and
stored by the Sponsor, for use by other researchers including those outside of the study.
With the patient’s approval and as approved by local IRB/EC, de-identified biological
samples will be stored with the same goal as the sharing of data.
During the study, an individual patient can choose to withdraw consent to have biological
specimens stored for future research. However, withdrawal of consent with regard to
biological sample storage may not be possible after the study is completed.
10.1.5.
Key Roles and Study Management
Study Sponsor:
SAE Reporting:
Stemline Therapeutics, Inc.
750 Lexington Avenue
4th floor
New York, NY 10022
Telephone: 1-646-502-2310
STML-901-0119_PV@TigermedGrp.com
10.1.6.
Clinical Monitoring
Clinical site monitoring is conducted to ensure that the rights and well-being of trial
participants are protected, that the reported trial data are accurate, complete, and
verifiable, and that the conduct of the trial is in compliance with the currently approved
protocol/amendment(s), with Good Clinical Practice (GCP), and with applicable
regulatory requirement(s).
•
Monitoring for this study will be performed by the Sponsor or designee.
•
Details of clinical site monitoring are documented in a Clinical Monitoring Plan
(CMP). The CMP describes in detail who will conduct the monitoring, at what
frequency monitoring will be done, at what level of detail monitoring will be
performed, and the distribution of monitoring reports.
10.1.7.
Quality Assurance and Quality Control
Each clinical site will perform internal quality management of study conduct, data and
biological specimen collection, documentation and completion.
Confidential
Page 53 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
Quality control (QC) procedures will be implemented beginning with the data entry
system and data QC checks that will be run on the database will be generated. Any
missing data or data anomalies will be communicated to the sites for
clarification/resolution.
Following written standard operating procedures (SOPs), the monitors will verify that the
clinical trial is conducted, and data are generated in compliance with the protocol, GCP,
and applicable regulatory requirements.
The investigational site will provide direct access to all trial related sites, source
data/documents, and reports for the purpose of monitoring and auditing by the Sponsor,
and inspection by local and regulatory authorities.
10.1.8.
Data Handling and Record Keeping
The Investigator and designees agree to maintain accurate eCRFs and source
documentation as part of case histories. Source documents are the originals of any
documents used by the Investigator or Sub-Investigator or hospital/institution that allow
verification of the existence of the patient and substantiate the integrity of the data
collected during the study.
The Sponsor will develop the Electronic Data Capture (EDC) environment to the study
center. eCRFs must completed only by persons designated by the Investigator. All data
entered into the eCRF must also be available in the source documents. The Investigator
will allow the Sponsor designated representatives and regulatory bodies to have direct
access to the source documents to verify the data reported in the eCRFs.
The CRA will review the eCRF data against source documents according to the CMP.
Investigators are responsible for ensuring the accuracy and quality of the eCRF data.
A record of patient screen failures will be maintained for patients who do not qualify for
enrollment. Minimal data entry is required for screen failed patients.
Essential documents should be retained for a minimum of 2 years after the last approval
of a marketing application in an ICH region and until there are no pending or
contemplated marketing applications in an ICH region or at least 2 years have elapsed
since the formal discontinuation of clinical development of the investigational product.
However, these documents should be retained for a longer period if required by the
applicable local requirements.
ICH requires that patient identification codes be retained for at least 15 years after the
completion or discontinuation of the study
10.1.9.
Protocol Deviations
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or other
study requirements documented in any study-specific operational document. The
noncompliance may be either on the part of the patient, the Investigator, or the study site
staff. As a result of deviations, corrective actions may need to be developed by the site
and implemented promptly.
It is the responsibility of the Investigator to use continuous vigilance to promptly identify
and report protocol deviations. All deviations must be addressed in study source
Confidential
Page 54 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
documents and reported to the Sponsor. Protocol deviations must be sent to the reviewing
IRB/EC per their policies. The site Investigator is responsible for knowing and adhering
to the reviewing IRB/EC requirements.
10.1.10.
Publication and Data Sharing Policy
All information regarding SL-901 supplied by the Sponsor to the Investigator or
generated as a result of any clinical studies is privileged and confidential information
belonging to the Sponsor.
The Investigator agrees to use the Sponsor’s confidential information solely to
accomplish the study and will not use such information for any other purposes without
the prior written consent of the Sponsor.
It is understood that there is an obligation to provide the Sponsor with complete and
accurate data obtained during the study. The information obtained from the clinical study
will be used towards the development of SL-901 and may be disclosed by the Sponsor to
regulatory authorities, other Investigators, corporate partners, or consultants as required.
It is anticipated that the results of this study may be presented at scientific meetings
and/or published in a peer reviewed scientific or medical journal. A Publications
Committee, comprised of Investigators participating in the study and representatives from
the Sponsor, as appropriate, will be formed to oversee any publication or presentation of
the study results, which will reflect the experience of all participating study centers. All
publications and presentations must be approved in advance by the Sponsor in its sole
discretion. Subsequently, individual Investigators may publish results from the study in
compliance with their agreement with the Sponsor.
10.1.11.
Financial Disclosure Reporting Obligations
Investigators and Sub-Investigators are required to provide financial disclosure
information to the Sponsor to permit the Sponsor to fulfill its regulatory obligation.
Investigators and Sub-Investigators must commit to promptly updating the information if
any relevant changes occur during the study and for a period of one year after the
completion of the study.
Confidential
Page 55 of 56
.


Stemline Therapeutics, Inc.
STML-901-0119 (Version 3.0)
13 October 2022
.
11.
REFERENCES
Ahn. 1998. "An evaluation of phase I cancer clinical trial designs." Statistics in Medicine
17 (14): 1537-1549.
Courtney. 2010. "The PI3K pathway as drug target in human cancer." J Clin Oncol 28 (6)
1075-83.
Gastontis. 1992. "Bayesian methods for phase I clinical trials." Statistics in Medicine 11
(10): 1377-1389.
Greenwell. 2017. "PI3K Inhibitors: Understanding Toxicity." Oncology (31) 821-828.
1997. "International Conference on Harmonisation."
Krause. 2018. "Copanlisib for treatment of B-cell malignancies: the development of a
PI3K inhibitor with considerable differences to idelalisib." Drug Design,
Development and Therapy (12) 2577-2590.
Liu. 2009. "Targeting the phosphoinositide 3-kinase pathway in cancer." Nature
Reviews/Drug Discovery (8) 627-644.
Storer. 1989. "Design and analysis of phase I clinical trials." Biometrics 45 (3): 925-937.
Confidential
Page 56 of 56
.


STML-901-0119_Protocol_v3.0_clean_13Oct20
22_RSP (1)
Final Audit Report
2022-10-14
Created:
By:
Status:
Transaction ID:
2022-10-14
Signed
"STML-901-0119_Protocol_v3.0_clean_13Oct2022_RSP (1)" His
tory
Document created by 
2022-10-14 - 12:42:39 PM GMT- IP address: 
Document emailed to 
 for signature
2022-10-14 - 12:43:15 PM GMT
Email viewed by 
2022-10-14 - 12:43:19 PM GMT- IP address: 
Document e-signed by 
Signature Date: 2022-10-14 - 3:25:18 PM GMT - Time Source: server- IP address: 
Agreement completed.
2022-10-14 - 3:25:18 PM GMT

SAP_001.pdf: 
STUDY CODE: STML-901-0119 
STATISTICAL ANALYSIS PLAN (SAP) 
A Phase 1, Open-label, Dose-escalation Study of the PI3K Inhibitor SL-
901 in Patients with Advanced Solid Tumors 
Sponsor: 
Stemline Therapeutics, Inc. 
750 Lexington Ave. 11th Floor 
New York, NY 10022 
EudraCT-No.: 
2019-004135-22 
Investigational medicinal Product: SL-901 
Development Phase: 
Phase I 
Indication: 
Advanced Solid Tumors 
Date of First Patient In:  
25MAR2021 
Date of Last Patient Out: 
24APR2023 
SAP Version and date  
Protocol Version and date 
1.0 21JUN2023 
2.0 06OCT2020 
STATEMENT OF CONFIDENTIALITY 
The study is conducted according to the protocol and in compliance with International Conference of Harmonisation - 
Good Clinical Practice (ICH-GCP), the Declaration of Helsinki (and subsequent amendments) and the applicable 
regulatory requirements. 
This document contains confidential information of Menarini Group. Do not copy or distribute without written 
permission from the sponsor. 
NCT #: NCT05382936


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 2 of 49 
 
 
 
 
SIGNATURE PAGE 
I have read this report and confirm that to the best of my knowledge it accurately describes the planned 
statistical analyses of the study. 
Author 
 
28JUN2023 
 
 
Signature 
Date 
 
Reviewer 
 
28JUN2023 
 
Signature 
Date 
 
Approver 
 
27JUN2023 
 
 
Signature 
Date 
 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 3 of 49 
 
 
Table of contents 
 
 
1. 
Version History .................................................................................................................................................................. 5 
2. 
List of abbreviations .......................................................................................................................................................... 6 
3. 
Introduction ...................................................................................................................................................................... 10 
3.1. 
Changes from study protocol ....................................................................................................................................... 10 
4. 
Study overview ................................................................................................................................................................ 11 
4.1. 
Study objectives ........................................................................................................................................................... 11 
4.1.1. 
Primary objective(s) ................................................................................................................................................ 11 
4.1.2. 
Secondary objective(s) ............................................................................................................................................ 11 
4.1.3. 
Exploratory objective(s) .......................................................................................................................................... 11 
5. 
Investigational plan .......................................................................................................................................................... 11 
5.1. 
Study configuration and structure ................................................................................................................................ 11 
5.2. 
Schematic study design ............................................................................................................................................... 14 
5.3. 
Study flow chart........................................................................................................................................................... 14 
5.4. 
Study Endpoints ........................................................................................................................................................... 18 
5.4.1. 
Primary endpoints ................................................................................................................................................... 18 
5.4.2. 
Secondary endpoints ............................................................................................................................................... 18 
5.4.3. 
Exploratory endpoints ............................................................................................................................................. 19 
5.4.4. 
Safety endpoints ...................................................................................................................................................... 19 
6. 
General specifications ...................................................................................................................................................... 19 
6.1. 
Data validation ............................................................................................................................................................. 19 
6.2. 
Computer system and software used ........................................................................................................................... 19 
6.3. 
Coding systems ............................................................................................................................................................ 20 
6.3.1. 
Clinical Terms ......................................................................................................................................................... 20 
6.3.2. 
Drugs ....................................................................................................................................................................... 20 
6.3.3. 
Classification criteria ............................................................................................................................................... 20 
6.4. 
Report type, language, format ..................................................................................................................................... 20 
6.5. 
Standard Operating Procedures (SOPs) to be followed ............................................................................................... 21 
6.6. 
Data Transfer Agreements ........................................................................................................................................... 21 
7. 
Definitions and general methodology .............................................................................................................................. 22 
7.1. 
Data quality assurance ................................................................................................................................................. 22 
7.2. 
General considerations and key definitions ................................................................................................................. 22 
7.2.1. 
General considerations ............................................................................................................................................ 22 
7.2.2. 
Key definitions ........................................................................................................................................................ 22 
7.3. 
Analysis populations .................................................................................................................................................... 25 
7.4. 
On study and pre-study closure activities .................................................................................................................... 25 
7.4.1. 
Data monitoring ...................................................................................................................................................... 25 
7.4.2. 
Protocol Deviations and Data Review Meeting ...................................................................................................... 26 
8. 
Determination of sample size ........................................................................................................................................... 27 
9. 
Randomization Methodology ........................................................................................................................................... 27 
10. 
Stopping Rules and Blinding ....................................................................................................................................... 27 
10.1. 
Stopping Rules ............................................................................................................................................................. 27 
10.2. 
Blinding ....................................................................................................................................................................... 27 
11. 
Statistical analysis and methods .................................................................................................................................. 27 
11.1. 
Multiplicity adjustment ................................................................................................................................................ 27 
11.2. 
Descriptive statistics .................................................................................................................................................... 27 
11.3. 
Data imputation ........................................................................................................................................................... 29 
11.4. 
Patient disposition and Baseline tables ........................................................................................................................ 31 
11.5. 
Safety analysis ............................................................................................................................................................. 33 
11.5.1. 
Safety assessments .................................................................................................................................................. 33 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 4 of 49 
 
 
11.5.2. 
Adverse Events ........................................................................................................................................................ 34 
11.5.3. 
Vital Signs ............................................................................................................................................................... 35 
11.5.4. 
Physical Examination .............................................................................................................................................. 36 
11.5.5. 
12-lead ECG ............................................................................................................................................................ 36 
11.5.6. 
Echocardiogram ...................................................................................................................................................... 36 
11.5.7. 
Safety laboratory tests ............................................................................................................................................. 37 
11.5.8. 
ECOG Performance Status ...................................................................................................................................... 37 
11.5.9. 
Reproductive System Findings and Pregnancy Test ............................................................................................... 37 
11.5.10. 
Treatment exposure and compliance ....................................................................................................................... 37 
12. 
Efficacy evaluations .................................................................................................................................................... 38 
12.1. 
Efficacy analysis .......................................................................................................................................................... 38 
12.1.1. 
Best Overall Response and Objective Response ..................................................................................................... 38 
12.1.2. 
Duration of Response .............................................................................................................................................. 39 
12.1.3. 
Progression-free survival ......................................................................................................................................... 40 
12.1.4. 
Overall Survival ...................................................................................................................................................... 42 
12.2. 
Subgroup analyses ....................................................................................................................................................... 43 
12.3. 
Pharmacokinetic analysis............................................................................................................................................. 43 
13. 
Tables, listings and figures .......................................................................................................................................... 46 
13.1. 
Statistical Analysis Report ........................................................................................................................................... 46 
13.2. 
Index of TLFs .............................................................................................................................................................. 47 
13.2.1. 
Tables ...................................................................................................................................................................... 47 
13.2.2. 
Listings .................................................................................................................................................................... 48 
13.2.3. 
Figures ..................................................................................................................................................................... 49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 5 of 49 
 
 
 
1. Version History 
 
Version Date 
Author 
Description for Revision 
1.0 
23MAY2023 
 
 
This is the first issue of this document 
 
 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 6 of 49 
 
 
2. List of abbreviations  
ADaM 
Analysis Data Model 
ADR 
Adverse Drug Reaction 
AE 
Adverse Event 
ALT 
Alanine Aminotransferase 
AML 
Acute Myeloid Leukemia 
ANC 
Absolute Neutrophil Count 
AST 
Aspartate Aminotransferase 
ATC 
Anatomical Therapeutic Chemical Classification System 
AUC 
Area Under Curve 
AUCinf 
AUC from time of dosing extrapolated to infinity 
%AUCextrap 
Percentage of AUCinf due to extrapolation from Tlast to infinity 
AUClast 
Area under the curve from the time of dosing to the time of the last 
measurable concentration (Tlast) 
AUCTau 
The partial area from dosing time to dosing time plus dose interval (Tau)  
b.i.d. 
bis in die (twice daily) 
BLQ 
Below the Lower Limit of Quantification 
BMI 
Body Mass Index 
BOR 
Best Overall Response 
BP 
Blood Pressure 
BR 
Breath Rate 
BUN 
Blood Urea Nitrogen 
CA 
Competent Authority 
Cavg 
Average concentration 
CDB 
Clinical Database 
CDISC 
Clinical Data Interchange Standards Consortium 
CHF 
Congestive Heart Failure 
CLss/F 
Apparent Clearance at steady state 
Clast 
Observed concentration corresponding to Tlast 
Cmax 
Maximum observed concentration 
Cmin 
Minimum observed concentration occurring at time Tmin 
CI 
Confidence Interval 
CR 
Complete Response 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 7 of 49 
 
 
CRC 
Cohort Review Committee 
CRF 
Case Report Form 
CRO 
Contract Research Organization 
CRR 
Complete Response Rate 
CS 
Clinically Significant 
CSP 
Clinical Study Protocol 
CTCAE 
Common Terminology Criteria for Adverse Events 
CTLS 
Clinical Tumor Lysis Syndrome 
CV 
Coefficient of Variation 
CYP 
Cytochromes  
DC 
Disease Control 
DCR 
Disease Control Rate 
DLT 
Dose Limiting Toxicity 
DM 
Data Management 
DOCR 
Duration of Complete Response 
DOR 
Duration of Response 
DRM 
Data Review Meeting 
DSM 
Drug Safety Manager 
DSRC 
Data Safety Review Charter 
DSUR 
Development Safety Update Report 
ECG 
Electrocardiogram 
ECOG 
Eastern Cooperative Oncology Group  
eCRF 
electronic Case Report Form 
EDC 
Electronic Data Capture 
EOT 
End of Treatment 
F 
Bioavailability 
FFPE 
Formalin-Fixed Paraffin-Embedded 
GCP 
Good Clinical Practice 
GGT 
Gamma-Glutamyl Transpeptidase 
GM 
Geometric Mean 
HDPE 
High-Density Polyethylene 
HM 
Haematologic Malignancies 
HR 
Heart Rate 
IB 
Investigator’s Brochure 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 8 of 49 
 
 
ICF 
Informed Consent Form 
ICH 
International Conference on Harmonisation 
iDSMB 
Independent Data Safety Monitoring Board 
IMP 
Investigational Medicinal Product 
INR 
International Normalized Ratio 
IRB 
Institutional Review Board 
ITT 
Intent-to-treat 
IVRS 
Interactive Voice Response System 
IWRS 
Interactive Web Response System 
LDH 
Lactate Dehydrogenase 
LLT 
Lowest Level Term 
LOCF 
Last observation carry forward 
LTLS 
Laboratory Tumor Lysis Syndrome 
MedDRA 
Medical Dictionary for Regulatory Activities 
MTD 
Maximum Tolerated Dose 
NC 
Not Calculated 
NCI 
National Cancer Institute 
NE 
Not Evaluable 
NSADR 
Non-serious Adverse Drug Reaction 
NSAE 
Non-serious Adverse Event 
ODS 
Output Delivery System 
OR 
Objective Response 
ORR 
Objective Response Rate 
OS 
Overall Survival 
PBMC 
Peripheral Blood Mononuclear Cell 
PD 
Pharmacodynamics 
PD 
Progressive Disease 
PFS 
Progression-free survival 
PI3K 
Phosphoinositide 3-kinase 
PK 
Pharmacokinetics 
PP 
Per-protocol 
PR 
Partial Response 
PS 
Performance Status 
PT  
Preferred Term 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 9 of 49 
 
 
QA 
Quality Assurance 
q.d. 
quaque die (every day) 
QTcF 
Fridericia-corrected QT interval 
RBC 
Red Blood Cells 
RECIST 
Response Evaluation Criteria in Solid Tumors 
RO 
Receptor Occupancy 
SADR 
Serious Adverse Drug Reaction 
SAE 
Serious Adverse Event 
SAP 
Statistical Analysis Plan 
SAR 
Statistical Analysis Report 
SD 
Stable Disease 
SD 
Standard Deviation 
SDTM 
Study Data Tabulation Model 
SmPC 
Summary of Product Characteristics 
SOC 
System Organ Class 
SOP 
Standard Operating Procedure 
sUA 
serum Uric Acid 
SUSAR 
Suspected Unexpected Serious Adverse Reaction 
TA 
Tumor Assessment 
TEAE 
Treatment Emergent Adverse Event 
Tlast 
Time of last measurable observed concentration 
TLS 
Tumor Lysis Syndrome 
Tmax 
Time of maximum observed concentration 
TMF 
Trial Master File 
Tmin 
Time of minimum observed concentration 
UA 
Uric Acid 
UGT 
Uridine Diphosphate Glucuronosyltransferase  
ULN 
Upper Limit of Normal 
Vz/F 
Apparent volume of distribution based on the terminal phase 
WBC 
White Blood Cells 
WHO 
World Health Organization 
 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 10 of 49 
 
 
3. Introduction 
The purpose of this document is to provide further details about the statistical analysis methods 
specified in the final study protocol Version 2.0 dated 06OCT2020 and subsequent amendments. The 
SAP follows the principles of the guidelines ICH Topic E3 and E9 regarding the structure and content of 
clinical study reports and regarding statistical principles for clinical trials.  
The SAP will be finalized and signed prior to locking the database. 
The sponsor of the study is Menarini Stemline. 
Section 4 provides a study overview and presents the study objectives. In Section 5 the study design 
and the endpoints are described in a detailed way and also the study flow chart, taken from the Clinical 
Study Protocol v2.0, is reported. Section 6 presents some general specifications for the data validation, 
the computer systems, software and coding systems used. All definitions and the general methodology 
for the study activities are reported in Sections 7 through 10, while the analyses and summaries that 
will be produced and detailed specifications on the statistical methodology are presented in Sections 11 
and 12. Section 13 provides the complete index of tables, listings and figures for the Statistical Analysis 
Report that will be generated at the end of the study. 
3.1. Changes from study protocol 
Since the PK run-in period is included in the DLT assessment period, the DLT population definition has 
been modified so that in order to be considered DLT evaluable a patient must have taken also the full 
dose during the run-in period in addition to at least 75% of the planned SL-901 doses in Cycle 1. 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 11 of 49 
 
 
4. Study overview 
SL-901 is an orally bioavailable investigational anticancer drug aimed to treat patients whose cancers 
harbor an overactive phosphoinositide 3-kinase (PI3K) signaling. 
This is a Phase I, open-label, dose-escalation and cohort expansion study in two parts: In Part 1a, 
escalating doses and 2 schedules of SL-901 will be evaluated in patients with advanced solid tumors, 
to identify the maximum tolerated dose (MTD) and determine the regimen for Part 1b. In Part 1b, the 
clinical activity of SL-901 at the selected dose and schedule will be further characterized in patients 
with advanced solid tumors known to have specific genetic alterations and who may derive benefit from 
treatment with a PI3K inhibitor. 
The study was stopped early and Part 1b was not started. 
4.1. Study objectives 
4.1.1. Primary objective(s) 
• To identify the MTD of SL-901; 
• To identify an appropriate dosing regimen for further investigation of SL-901; 
• To characterize the pharmacokinetics (PK) profile of SL-901; 
• To generate clinical safety data and perform initial assessment of the safety profile of SL-
901. 
4.1.2. Secondary objective(s) 
• To characterize the pharmacodynamics (PD) of SL-901; 
• To assess preliminary clinical activity of SL-901. 
4.1.3. Exploratory objective(s) 
Not Applicable. 
5. Investigational plan 
5.1. Study configuration and structure 
This clinical study includes 2 parts. 
Dose-Escalation (Part 1a) 
This is an open-label, dose-escalation, and regimen-finding study to investigate the safety, PK, and PD 
of SL-901 in patients with advanced solid tumors. In Part 1a, adverse events (AEs) occurring during the 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 12 of 49 
 
 
first cycle of treatment will be considered for the assessment of Dose Limiting Toxicities (DLTs), with 
continued evaluation of AEs in subsequent treatment cycles for further characterization of the safety of 
SL-901. This part will follow a 3+3 dose-escalation design to determine the MTD of SL-901 when 
administered on both a QD and BID schedule; single and multiple dose PK assessments will be 
performed to characterize the exposure of SL-901. The dose-escalation scheme to be followed is 
based on a modified Fibonacci sequence schema, which also is commonly employed in Phase 1 dose-
finding oncology studies. 
The SL-901 starting dose will be 20 mg on both the QD and BID schedule. The QD and BID schedules 
are planned to be tested in parallel, with enrolment to the current cohort for each schedule conducted 
on an every other patient basis.  
 
Table 1: Planned SL-901 Dose Levels in Part 1a 
 
 
A DLT occurring during the Run-in PK period or in Cycle 1 is defined as any of the following AEs for 
which there is a reasonable possibility that SL-901 caused the event. 
•   Any ≥Grade 3 non-hematologic AEs, with the exceptions of: 
-  Grade 3 nausea, vomiting, diarrhea, constipation, fever, fatigue, or skin rash that resolves to 
Grade <3 within 72 hours. 
-  Grade 3 laboratory abnormalities that are not associated with symptoms and resolve to 
Grade 1 or baseline by C1D28 (unless otherwise specified). 
•   Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with >Grade 1 bleeding or requirement 
for platelet transfusion. 
•   Grade 4 neutropenia lasting >5 days. 
•   Febrile neutropenia (absolute neutrophil count [ANC] <1×109/L with fever ≥38.5°C) of any 
duration. 
•   Persistent anemia (i.e., lasting >96 hours despite >2 red blood cell [RBC] transfusions). 
•   ≥Grade 3 transaminase (AST/ ALT) elevation. 
•   Any toxicity resulting in >7 held/skipped doses. 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 13 of 49 
 
 
•   Any other significant toxicity considered by the Investigator or the Sponsor to be dose-limiting 
(e.g., any toxicity considered at least possibly related to SL-901 that results in patient withdrawal 
during C1). 
In situations in which DLTs have occurred that would prevent further dose-escalation and are severe 
but not life-threatening (i.e., persistent Grade 3 fever, malaise), re-evaluation of specific dose cohorts 
may be considered with co-administration of appropriate supportive care agents (e.g., corticosteroids, 
anti-depressants) concomitant with SL-901 therapy. 
Patients who do not receive the complete run-in dose and at least 75% of the planned SL-901 doses in 
Cycle 1 and/or discontinue before completing study assessments through C2D1 for reasons other than 
DLT are to be replaced. 
The MTD is defined as the highest dose level at which no more than 1 of 6 subjects experience a DLT 
during the DLT assessment window (Run-in PK period and C1). An MTD will be identified for each 
dosing schedule. 
All dose-escalation steps and schedule recommendations will be made by a review committee, 
comprised of the study Investigators and Sponsor representatives, who will review the available safety 
and other relevant data to inform the decision. 
 
Expansion Cohorts (Part 1b) 
Up to 4 expansion cohorts at the MTD (or maximum tested dose if no MTD is identified, or dose below 
the MTD if there is evidence suggesting a more favorable risk/benefit profile) may be opened for 
enrolment with 6 to 12 patients in each cohort. Although decisions regarding dose-escalation will be 
made based on review of data from Part 1a, safety data will also be collected from all patients in Part 
1b and reviewed periodically by the Sponsor and Investigators. Any detected cumulative toxicity may 
require later dose reductions or other action as appropriate, including further refinement of the MTD. 
This part of the study was not started. 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 14 of 49 
 
 
5.2.  Schematic study design 
Screening assessments are performed subsequent to the patient providing an informed consent and 
within 28 days before the first administration of SL-901 at the Run-in PK sampling day, unless 
otherwise specified.  
In both study parts a treatment cycle is considered to be 28 days, with daily dosing throughout the 
cycle. 
All patients will receive SL-901 as a single agent in an open-label fashion; study drug will be dispensed 
to patients at scheduled study center visits on a per-cycle basis. SL-901 capsules (20 mg and 60 mg) 
are packaged into 50-cc high-density polyethylene (HDPE) bottles, 14 capsules per bottle. 
Tumor assessment will occur at Screening (for identification of baseline disease) and every 2 cycles of 
treatment thereafter. Response will be evaluated using Response Evaluation Criteria in Solid Tumors 
(RECIST) v1.1.  
In Part 1a, a serially sampled PK profile will be obtained for a single dose (Run-in PK sampling) and at 
steady-state (C1D15); in Part 1b, the PK sample collection schedule will be informed by data collected 
in Part 1a. 
All Serious Adverse Events (SAEs) and non-SAEs will be recorded in the study’s clinical database from 
the day of informed consent signature (SAEs) or from the day of first exposure to SL-901 (AEs) through 
30 days after the last dose of SL-901. 
After completion of the End of Treatment (EOT) visit, patients will then be followed every 90 days for 
survival status for 12 months. The survival follow-up may be by telephone contact. If the patient 
discontinued study drug for reasons other than progressive disease, disease assessments should 
continue to be performed on an every 8-week basis (±1 week) through 6 months after the first study 
drug dose and then on an every 90-day basis or until, in the judgment of the Investigator, there is 
evidence of relapsed or progressive disease. 
5.3. Study flow chart 
The schedule of assessments for the study is provided in Table 2 (Screening period, Run-in 
pharmacokinetic [PK] and Cycles 1-2) and Table 3 (Cycle 3 and beyond). PK assessment schedule is 
provided in Table 4. 
 
 
 
 
 
 
 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 15 of 49 
 
 
 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 16 of 49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 17 of 49 
 
 
 
 
 
 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 18 of 49 
 
 
 
5.4.       Study Endpoints 
5.4.1. Primary endpoints 
• Safety endpoints include  
o identification of DLTs;  
o rate of treatment-emergent adverse events (TEAEs) and SAEs;  
o identification of abnormalities in physical examination, vital signs, clinical laboratory 
evaluations; 
o ECG findings. 
• PK endpoints include  
o assessment of SL-901 plasma concentration over time;  
o assessment of any changes in the PK properties of SL-901 between initial 
administration and steady-state and between cycles of treatment;  
o explore the correlation between PK parameters and toxicity. 
5.4.2. Secondary endpoints 
• PD assessment of target phosphorylation will be performed using a PI3K pathway triple 
assay (p-AKT, p-p70S6K, and p-GSK3) in platelet-rich plasma and/or tumor tissue and 
using immunofluorescence for gamma H2AX in PBMCs. 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 19 of 49 
 
 
• Clinical activity endpoints include  
o Objective Response Rate (ORR); 
o Disease Control Rate (DCR) 
o Complete Response Rate (CRR);  
o Duration of Response (DOR);  
o Duration of Complete Response (DOCR) 
o Progression-free survival (PFS); 
o Overall Survival (OS). 
5.4.3. Exploratory endpoints 
Not applicable. 
5.4.4. Safety endpoints 
The Safety endpoints are included among the planned primary endpoints. Please refer to 
paragraph 5.4.1. 
6. General specifications 
6.1. Data validation 
Medidata Classic Rave ® 2020.3. 2 and following software release will be used as Electronic Data 
Capture (EDC) system for data entry, by site personnel and for data cleaning and data locking by 
the Menarini Ricerche Data Management team. 
The eCRF data are elaborated to create the SDTM (v1.8) and ADaM (v2.1) CDISC standard 
datasets. 
6.2. Computer system and software used 
The software used for all summary statistics and statistical analyses will be SAS Studio ® 9.04.01 
or higher (SAS Institute, Inc.). All tables and listings will be produced using PROC REPORT or 
procedure specific output displays using output delivery system (ODS). The summary tables and 
listings will use SAS monospace font of size 6. The default page type will be A4 and the default 
page orientation will be landscape. 
The PK parameters will be determined from the individual plasma concentration time curves using 
non-compartmental methods with Phoenix™ WinNonlin® software, version 6.4 or higher 
(Pharsight Corp., Mountain View, California). 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 20 of 49 
 
 
6.3. Coding systems 
6.3.1. Clinical Terms 
Concomitant diseases, medical procedures, and Adverse Events will be coded with MedDRA 
version 23.1 or subsequent versions. 
6.3.2. Drugs 
Drugs will be coded with WHO (ATC coding system) Drug version Mar-2021 or subsequent 
versions. 
6.3.3. Classification criteria 
Adverse Events will be graded for severity using the classifications of Common Terminology 
Criteria for Adverse Events (CTCAE) Version 5.0 (November 27, 2017).  
6.4. Report type, language, format 
The statistical output will be in word and .pdf format and in English language.  
Dates will be presented with the DDMMMYYYY format. 
Counts and percentages:  
 
<group 1> 
xxx (xx.xx%) 
Counts and percentages including also the count of the event of interest will be displayed in two 
separated columns: 
n (%) 
No. of events 
xx (xx.xx %) 
xxx 
 
 
Descriptive statistics:             n 
 
xxx 
 
 
 
 
 
Mean  
xxx.xx 
 
 
 
 
 
Median 
xxx.xx 
 
 
 
 
 
SD 
 
xxx.xxx 
 
 
 
 
 
Minimum 
same precision as individual value 
 
 
 
 
 
Maximum 
same precision as individual value 
 
 
 
 
 
 
In general, the following rule will be applied for decimal place: 
o 
Minimum, maximum: one decimal place 
o 
Arithmetic mean and median: one more decimal than minimum/maximum 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 21 of 49 
 
 
o 
SD: one more decimal than arithmetic mean/median 
o 
N: no decimal places  
 
Character values will be left aligned. 
Numeric values will be decimal-point aligned. 
6.5. Standard Operating Procedures (SOPs) to be followed 
1Code 
Title 
MR-GCS-DMST-210_SOP 
Statistical Analysis Plan (SAP) 
MR-GCS-DMST-211_SOP 
Statistical Programs Writing 
MR-GCS-DMST-211.3_WI 
TLF programming 
MR-GCS-CP&P-504 
Use and management of Phoenix® WinNonlin® and 
pharmacokinetic data flow 
MR-GCS-CP&P-505 
Standard methods for non-compartmental analysis of 
pharmacokinetic data 
 
6.6. Data Transfer Agreements 
Data not directly entered in eCRF like (and not limited to): 
- PK concentrations – 
 “STML_901_0119_PK_Concentrations_DTA V1.0”  
- PK analysis results – Clinical Pharmacology and Pharmacometrics team Menarini Ricerche S.p.A 
“STML_901_0119_PK_DTA V1.0”  
- PD results - 
 
are transferred to the Sponsor based on specific Data Transfer Agreements (DTA).  
For the details regarding DTAs  and the management of the received data, please refer to the Clinical 
Data Management Plan. 
 
 
 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 22 of 49 
 
 
7. Definitions and general methodology 
7.1. Data quality assurance  
All tables, figures and data listings to be included in the report will be independently checked for 
consistency, integrity and in accordance with Menarini Ricerche standard procedures.  
7.2. General considerations and key definitions 
7.2.1. General considerations 
Study day is defined as the number of days from the date of first dose of SL-901 to the event/visit 
date. For dates equal to or later than the first dose of study drug, study day is calculated as follows: 
Study Day = Event or Visit Date – First Dose Date + 1 
 
For dates prior to the first dose of study drug, study day is calculated as follows: 
Study Day = Event or Visit Date – First Dose Date 
 
One (1) month will be considered to be equal to 30.4375 days when calculating durations or 
survival times in months.  
7.2.2. Key definitions 
Baseline 
Baseline is defined as the last non-missing assessment prior to the date and time of the first SL-
901 dose.  
Change from Baseline 
Change from Baseline (absolute value) = post-baseline value – baseline value. 
Adverse Events (AEs)  
An AE is any untoward medical occurrence in a study patient who is administered a medicinal 
product (study drug), regardless whether or not considered drug-related. An AE can therefore be 
any unfavorable and unintended sign including abnormal laboratory/examination findings, 
symptoms, or disease(s) temporally associated with the use of study drug, whether or not related 
to study drug. An AE can arise from any use of the drug (e.g., off-label use, use in combination 
with another drug) and from any route of administration, formulation, or dose, including an 
overdose. 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 23 of 49 
 
 
 
Treatment-Emergent Adverse Events (TEAEs)  
 
If an Adverse Event occurs for the first time or if it worsens in terms of grade, seriousness or 
severity on or after the first on or after the date and time of the first dose of SL-901 and up to 30 
days after the last dose of SL-901, it will be classified as TEAE, otherwise it will be classified as 
non-TEAE. Where an AE date is partial or missing, and it is unclear whether the AE is treatment-
emergent, the AE will be assumed to be treatment-emergent. 
 
Adverse Drug Reactions (ADRs)  
 
Untoward and unintended responses to an Investigational Medicinal Product (IMP) related to any 
dose administered. The definition also covers medication errors and uses outside what is foreseen 
in the protocol, including misuse and abuse of the product. The definition implies a ‘reasonable 
possibility of a causal relationship between the event and the IMP. This means that there are facts 
(evidence) or arguments to suggest a causal relationship. 
 
All AEs (including SAEs) are to be accurately recorded on the AE page of the patient’s electronic 
case report form (eCRF). Each event will be graded for severity using the classifications of NCI 
CTCAE (see section 6.3.3).  
o Grade 1 / Mild - AE that disappears or is easily tolerated on continuation of study drug; 
o Grade 2 / Moderate – AE that disappears or is easily tolerated on continuation of study 
drug; 
o Grade 3 / Severe - AE sufficiently discomforting to cause interference with usual work 
activities; 
o Grade 4 / Life-threatening - AE that is potentially life-threatening.  
o Grade 5 / Fatal - Results in the patient’s death.  
 
A severe event is not necessarily a serious event. For example, a headache may be severe 
(interferes significantly with patient’s usual function) but would not be classified as serious unless it 
met one of the criteria for serious events as defined below. 
 
Serious Adverse Event (SAE) / Serious Adverse Drug Reaction (SADR)  
 
Any untoward medical occurrence or effect that at any dose:  
• 
Results in death.  


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 24 of 49 
 
 
• 
Is life-threatening. Life-threatening means that the patient was at immediate risk of death from 
the reaction as it occurred (i.e., it does not include a reaction which hypothetically might have 
caused death had it occurred in a more severe form). 
• 
Requires in-patient hospitalization or prolongation of existing hospitalization. Hospitalization 
admissions and/or surgical operations scheduled to occur during the study period, but planned 
before study entry are not considered adverse events if the illness or disease existed before 
the patient was enrolled in the study, provided that it did not deteriorate in an unexpected 
manner during the study (e.g. surgery performed earlier than planned). 
• 
Results in persistent or significant disability/incapacity or substantial disruption of 
• 
the ability to conduct normal life functions. 
• 
Results in a congenital anomaly/birth defect 
Any other AE/ADR which is not included in the above definitions will be considered as non-
serious. The Investigator should also promptly report all the SAEs to the Sponsor’s Drug Safety 
Manager. 
 
Algorithm for Causality Assessment of Adverse Events  
 
The causality (causal relationship to the study drug) of AEs will be assessed based on the 
following algorithm:  
1. Definitely related: An AE, including a laboratory test abnormality assessed as clinically 
significant (CS), is considered certainly related to a drug when it occurs in a plausible time 
relation to the administration of the drug, and which cannot be explained by concurrent 
disease or other drugs or chemicals. The response to withdrawal of the drug (de-challenge) 
should be clinically plausible. The event must be definitely related, pharmacologically or 
phenomenological, using a satisfactory re-challenge procedure if necessary.  
2. Probably related: An AE, including a laboratory test abnormality assessed as CS, is 
considered probably related to a drug when it occurs in a reasonable time relation to the 
administration of the drug, is unlikely to be attributed to concurrent disease or other drugs 
or chemicals, and which follows a clinically reasonable response on withdrawal (de-
challenge). Re-challenge information (AE reappearance after drug reintroduction) is not 
required to fulfil this definition.  
3. Possibly related: An AE, including a laboratory test abnormality assessed as CS, is 
considered possibly related to a drug when it occurs in a reasonable time relation to the 
administration of the drug, or it could also be explained by concurrent disease or other 
drugs or chemicals. Information on drug withdrawal (de-challenge) may be lacking or 
unclear.  


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 25 of 49 
 
 
4. 
Unlikely related: An AE, including a laboratory test abnormality assessed as CS, is 
considered unlikely related to a drug when other drugs, chemicals or underlying disease 
provide plausible explanations and/or the temporal relation to the administration of the drug 
makes a causal relation improbable. 
5. 
Unrelated: An AE, including a laboratory test abnormality assessed as CS, is considered 
not related to the use of a drug in case of existence of a clear alternative explanation and/or 
unreasonable temporal relationship, and/or non plausibility. 
An AE in which the relationship is ranked 1, 2, 3 is defined as an ADR. AEs ranked 4 or 5 are not 
considered as ADRs. 
7.3. Analysis populations 
The following analysis populations will be considered in the statistical analysis: 
▪ DLT population: All patients receiving the complete run-in dose and at least 75% of the 
planned SL-901 doses in Cycle 1 and completing study assessments through C2D1, or 
patients discontinuing Cycle 1 due to DLT irrespective of the SL-901 dose actually received. 
▪ Safety population: all patients enrolled into the study and who received any amount of SL-
901. 
▪ Efficacy population: all patients enrolled into the study and who received any amount of SL-
901 (it corresponds to the safety population).   
▪ Per Protocol (PP) population: all patients who received at least 1 cycle of treatment, have at 
least 1 post-baseline efficacy assessment, and have no major protocol violations.  
▪ PK population: all patients who receive at least one dose of SL-901 and have at least one 
PK sample collected and the corresponding PK concentration. . 
7.4. On study and pre-study closure activities 
7.4.1. Data monitoring 
This study will be monitored in accordance with the ICH Guidelines for GCP. 
In conjunction with the investigators, the Sponsor will constantly monitor the incoming safety data, 
especially TEAEs, SAEs and SUSARs to continuously assess the overall risk/benefit of the 
patients enrolled in this study and to take appropriate actions. 
The DM review is also intended as data quality check in order to verify the consistency of the data 
entered and identify any possible misconduct from the site. 
All monitoring activities will be described in detail in the study-specific monitoring plan. 
  
Data Safety Review Committee 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 26 of 49 
 
 
Weekly cohort review meetings and dose escalation meetings were regularly conducted during 
Part 1 to closely monitor the patients’ safety. 
  
7.4.2. Protocol Deviations and Data Review Meeting 
Critical, Major or minor protocol deviations are defined based on the impact on the efficacy or 
safety of study treatments.  
Before database lock, a data review meeting (DRM) will take place to identify protocol deviations. 
Major protocol violations will be discussed, and on a case-by-case basis it will be determined 
whether or not to exclude the patients from the Per Protocol population. The final decisions on 
which patients to include or exclude from the Per Protocol population will be finalized prior to 
database lock. 
Categories of protocol violations will be defined and will be integrated in the statistical analysis.  
Significant protocol violations that potentially compromise the data integrity and patients’ safety will 
be summarized on the Safety Population as follows: 
● The number and percentage of patients with a critical protocol deviation by cohort and overall 
and by type of deviation  
● The number and percentage of patients with a major protocol deviation by cohort and overall and 
by type of deviation  
● The number and percentage of patients with a minor protocol deviation by cohort and overall and 
by type of deviation  
• 
A by-patient listing of all critical protocol deviations. 
● A by-patient listing of all major protocol deviations. 
● A by-patient listing of all minor protocol deviations. 
 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 27 of 49 
 
 
8. Determination of sample size 
No formal sample size calculation is required in this Phase 1 dose-escalation and dose expansion 
study. For each dosing schedule, 3 to 6 patients are to be enrolled in each dose escalation cohort in 
Part 1a. Up to 60 patients in total are to be enrolled in the dose escalation cohorts. 
The total number of patients to be enrolled is dependent upon the observed safety profile, which will 
determine the number of patients per dose cohort, as well as the number of dose-escalations required 
to achieve the MTD. 
A sample size of at least 3 patients in each cohort, expanding to 6 patients in the event of a marginal 
DLT rate (33%), is a conventional approach in dose-escalation studies of investigational oncologic 
agents. 
Six to 12 patients in each expansion cohort (up to 4 cohorts) are to be enrolled in Part 1b. 
9. Randomization Methodology 
Not applicable. 
10. Stopping Rules and Blinding 
10.1. Stopping Rules 
Not applicable. 
10.2. Blinding 
This is an open-label study; thus, study subjects and investigators will not be blinded to treatment 
assignment.  
Unblinded safety data will be reviewed at all dose-escalation steps by the DSRC. 
11. Statistical analysis and methods 
11.1. Multiplicity adjustment 
Not applicable. 
11.2. Descriptive statistics 
All study variables (with the exception of PK variables) will be presented by cohort and overall 
separately for each study part, using the appropriate descriptive statistics according to the variable 
nature, unless otherwise specified: 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 28 of 49 
 
 
▪ 
Continuous variables: number of non-missing observations, arithmetic mean, standard 
deviation (SD), minimum, median, maximum; 
▪ 
Categorical variables: number of non-missing observations and column percentages (n, %), 
where percentage is calculated over the relative population; when tabulating categorical 
data, “missing” will be included as a category and the number of subjects with missing data 
will be presented. 
▪ 
Time to event variables: number of non-missing observations, number and percentage of 
events, number and percentage of censored observations, 1st quartile (Q1), median and its 
95% Confidence Interval (CI), 3rd quartile (Q3), Kaplan-Meier survival curves. 
 
The behaviour over time of study variables will be summarised by cohort and overall as follows: 
▪ 
Continuous variables: descriptive statistics for each assessment time point; 
▪ 
Categorical variables: descriptive statistics for each assessment time point. 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 29 of 49 
 
 
11.3. Data imputation  
Adverse Events 
Completely missing AE dates (i.e., missing day, missing month and missing year) will not be imputed. 
Partial AE start and stop dates will be imputed according to the rules as follows in a sequential 
fashion. 
In the imputation of missing or partial dates, if the imputed date is after min (death date, cut-off date), 
min (death date, cut-off date) will be used as the imputed date. 
 
AE Stop Date 
• If month and year are present, then impute as the last day of that month 
• If only the year is present, impute as December 31 of that year 
• If the stop date is entirely missing, assume the event is ongoing 
 
AE Start Date 
• If month and year are present, and are not equal to the month and year of the first dose, then 
imputed as the first day of the month 
• If month and year are present, and are equal to the month and year of first dose 
o If stop date is complete and earlier than the date of first dose, then impute as the first day 
of the month 
o Else impute as the date of first dose 
• If only the year is present, and the year is not equal to the year of the first dose, then impute as 
January 1 of the year 
• If only the year is present, and the year is equal to the year of the first dose 
o If stop date is complete and earlier than the date of first dose, then impute as January 1 of 
the year 
o If stop date is partially missing and the month and year of stop date are earlier than the 
month and year of first dose, then impute as January 1 of the year 
o Else impute as the date of first dose 
• If the start date is entirely missing 
o  If the stop date is complete and earlier than the date of first dose, then impute as January 
1 of the stop year 
o If the day of stop date is missing, and the month and year are earlier than the month and 
year of first dose, then impute as January 1 of the stop year 
o  If the day and month of stop date are missing, and the year is earlier than the year of first 
dose, then impute as January 1 of the stop year 
o Else impute as the date of first dose 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 30 of 49 
 
 
Prior and Concomitant Medications 
The same imputation rules as outlined for the Adverse Events will be used for Prior and Concomitant 
Medications. 
 
Post-treatment systemic anti-cancer therapy 
• 
In case of partial start date of post-treatment systemic anti-cancer therapy, the date will be 
imputed as the first day of the month but not earlier than the last dose date.  
• 
In case of completely missing start date, it will be imputed as: 
min [max(PD date + 1, last SL-901 dose date + 1), end date of new anti-cancer therapy]. 
 
Last study drug administration 
The following rules should be used for the imputation of date of last SL-901 administration: 
• 
If the date of last administration is completely missing and there is no EOT eCRF and no 
death date, the subject is considered as ongoing and the cut-off date should be used as the 
last dosing date. 
• 
If the date of last administration is completely or partially missing and the EOT eCRF is 
available (prior to any death date or withdrawal of consent date, if available): 
o Case 1: The date of last administration is completely missing, and the EOT visit date is 
complete, then this latter date should be used. 
o Case 2: Only Year(yyyy) of the dose end date is available and yyyy < the year of EOT date: 
Use Dec31yyyy 
o Case 3: Only Year(yyyy) of the dose end date is available and yyyy = the year of EOT date: 
Use EOT date 
o Case 4: Both Year(yyyy) and Month (mm) are available for the date of last administration, 
and yyyy = the year of EOT date and mm < the month of EOT visit: Use the last day of the 
Month (mm). 
o Use min (EOT date, death date) for all other cases. 
 
After imputation, compare the imputed date with the start date of that specific record, if the imputed 
date is < start date of that record: Use the start date of that record. 
 
Tumor Assessment 
Completely or partially missing Tumor Assessment (TA) dates will not be imputed. 
o In case date of last TA is missing and there are no previous TA dates, then the date of first 
study drug admin will be used for censoring 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 31 of 49 
 
 
o In case date of last TA is missing and there are previous TA dates, then the previous TA date 
will be used for censoring 
o If there are multiple scan dates associated with an evaluation, the earliest of the scan dates 
associated with the evaluation will be used as the date of assessment. 
 
Handling of PK concentrations Below the Lower Limit of Quantification and missing sampling 
timepoints 
In all data presentations (except listings), plasma concentration values below the lower limit of 
quantification (BLQ) will be set to zero before the tmax and to “missing” after the tmax. Data-
replacements will be implemented by the PK analyst from Clinical Pharmacology and 
Pharmacometrics department.  
In listings, BLQ values will be reported as “BLQ”. 
A footnote will be added to the listing, tables, and figures, to indicate the lower limit of quantification 
(LOQ) value.  
If more than half of the subjects in a given analyte/time point combination have values <BLQ, then the 
descriptive statistics will not be presented and instead displayed as BLQ for the mean and missing for 
all other statistics. 
If actual sampling time is missing, the nominal time will be used and flagged in the listings. 
11.4. Patient disposition and Baseline tables 
Patient Disposition 
Patient disposition will be tabulated by cohort and overall, separately for each study part, including the 
following: 
• 
Number of patients screened 
• 
Number (%) of screening failures, with reason for screening failure 
• 
Number (%) of patients treated (i.e. who received at least one SL-901 dose) 
• 
Number (%) of patients who are still on-treatment (based on the absence of the ‘Disposition 
Status - Treatment Discontinuation’ eCRF) 
• 
Number (%) of patients who discontinued study treatment (based on the presence of the 
‘Disposition Status - Treatment Discontinuation’ eCRF) 
• 
Reason for study treatment discontinuation (based on ‘Disposition Status - Treatment 
Discontinuation eCRF) 
• 
Number (%) of patients in each analysis population 
• 
Number (%) of patients who terminated the study with reason for termination (based on the 
‘Disposition Status - End of Study’ eCRF) 
 
Demographic and Baseline Characteristics 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 32 of 49 
 
 
Demographic and baseline characteristics will be summarized by cohort and overall, separately for 
each study part, on the Efficacy Population using descriptive statistics; the following variables will be 
displayed: 
• 
Age, sex, race, ethnicity 
• 
ECOG PS 
• 
Location of primary tumor, disease stage at screening, years from diagnosis (calculated as 
year of screening visit – year of diagnosis), disease stage at diagnosis, number and setting of 
previous lines of cancer treatment, best response to previous cancer treatment. 
• 
Tumor mutation status (Part 1a and Part 1b  
 
By-patient listings will be produced for demography, tumor history, ECOG PS and tumor mutation 
status. 
 
Medical History, Procedures and Prior Radiotherapy 
Medical history will be presented by cohort and overall, separately for each study part, using 
frequency counts and percentages on the Efficacy Population. 
Medical/Procedure History are those conditions which started and ended before the date and time of 
first SL-901 intake; concomitant medical conditions/procedures are the ones with an end date on or 
after the date and time of first SL-901 intake, or still ongoing). 
 
The following summaries will be produced by MedDRA system organ class (SOC) and preferred term 
(PT): 
• 
Medical History 
• 
Procedure History 
• 
Concomitant Medical Conditions 
• 
Concomitant Procedures 
 
Summary of prior radiotherapy will include time from last therapy to first dose of study drug, site of 
radiotherapy, response to treatment. 
 
Medical/Procedure history, concomitant medical conditions/procedures and prior radiotherapy will 
also be reported in by-patient listings. 
 
Prior and Concomitant Medications 
Prior and Concomitant Medications will be presented by cohort and overall, separately for each study 
part, using frequency counts and percentages on the Efficacy Population. 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 33 of 49 
 
 
Prior medications are those with start and end dates prior to the date and time of first SL-901 intake; 
concomitant medications are those with start date on or after the date and time of first SL-901 
administration; prior and concomitant medications are those with start date prior to the date and time 
of first SL-901 intake and end date on or after the date and time of first SL-901 intake or still ongoing. 
 
The following summaries will be produced by WHO Drug Global Dictionary PT and Anatomical 
Therapeutic Chemical (ATC) code level 4: 
• 
Prior Medications 
• 
Prior and Concomitant Medications 
• 
Concomitant Medications 
 
Prior, concomitant and prior and concomitant medications will be reported in by-patient listings. 
 
11.5. Safety analysis 
Safety and toxicity will be evaluated on the Safety population by means of descriptive statistics during 
each study part. Safety evaluations will be based on the incidence, relationship, severity grade, and 
seriousness of treatment emergent adverse events (TEAEs), ECOG performance status, vital signs, 
ECGs, physical examination, and laboratory tests of chemistry, hematology, and coagulation 
parameters, as well as dose modifications (interruptions/reductions) due to TEAEs, and treatment 
discontinuations due to TEAEs. In addition, study drug exposure and compliance will be summarized. 
11.5.1. 
Safety assessments 
Safety and tolerability endpoints will be derived from the following measurements/evaluations: 
-  Incidence, grade, seriousness, and causality of TEAEs; 
-  Physical examination; 
-  Vital signs; 
-  Safety laboratory tests (Haematology, Serum Chemistry and Coagulation); 
-  12-lead-ECG. 
-  ECOG PS 
and will be presented by cohort and overall, separately for each study part, on the Safety population, 
with the exception of DLTs which will be presented on the DLT population. 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 34 of 49 
 
 
11.5.2. 
Adverse Events 
All identified AEs are recorded and described on the appropriate AE page of the eCRF, except for 
those events occurring prior to the start of the screening period, which are recorded on the Medical 
History eCRF page. All Adverse Events (including non-TEAEs or AEs happening after End of Study 
Visit of the patient) recorded in the eCRF will be listed.  
 
The following definitions apply: 
• 
An AE is considered as treatment-related if has been reported as Definitely Related, Probably 
Related, Possibly Related or if the relationship is missing. 
• 
An AE is leading to drug interruption if action taken with study drug is “Drug interrupted” 
• 
An AE is leading to drug withdrawal if action taken with study drug is “Drug withdrawn” 
• 
An AE is leading to dose reduction if action taken with study drug is “Dose reduced” 
• 
An AE is leading to death if the outcome of the event is “Fatal” 
 
In all summaries, patients with more than one AE under the same SOC or PT are counted only once 
for that SOC or PT. 
For summaries by maximum CTCAE grade, patients with multiple events under the same SOC or PT 
will be counted only under the category of their most severe event within that SOC or PT. 
For summaries by relationship to study drug, events judged to be Definitely Related, Probably 
Related, Possibly Related will be considered as Treatment-related. 
 
Excluding the general summaries of TEAEs, all other tables will report both the number of patients 
experiencing events and the number of events. 
 
An overall summary of TEAEs will include the number of patients in the following categories:  
• 
Any TEAE 
• 
Any serious TEAE 
• 
Any related TEAE 
• 
Any serious related TEAE 
• 
Any TEAE by Relationship with study drug 
• 
Any TEAE by Outcome,  
• 
Any TEAE by CTCAE Grade 
• 
Any TEAE by Action Taken 
• 
Any TEAE by Pattern 
 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 35 of 49 
 
 
TEAEs will also be summarized by SOC and PT for the following categories: 
• 
DLTs 
• 
All TEAEs 
• 
TEAEs by Maximum Grade 
• 
TEAEs leading to drug interruption 
• 
TEAEs leading to drug withdrawal 
• 
TEAEs leading to dose reduction 
• 
TEAEs leading to death 
• 
Serious TEAEs (SAEs) 
• 
SAEs by Maximum Grade 
• 
Treatment-related TEAEs 
• 
Treatment-related TEAEs by Maximum Grade 
• 
Treatment-related TEAEs leading to drug interruption 
• 
Treatment-related TEAEs leading to drug withdrawal 
• 
Treatment-related TEAEs leading to dose reduction 
• 
Treatment-related TEAEs leading to death 
• 
Serious Treatment-related TEAEs 
• 
Serious Treatment-related TEAEs by Maximum Grade 
• 
 
 
All adverse events will be listed. At minimum the following information will be reported for all AEs 
listings: date of onset and resolution, study cycle of occurrence, duration in days, grade and 
seriousness of the event, relationship to study drug, action taken with study drug.   
Listings will be produced for all AEs, all TEAEs, DLTs, SAEs, Treatment-related TEAEs, Serious 
Treatment-related TEAEs. 
11.5.3. 
Vital Signs 
Vital signs will only be listed: 
• 
Height (cm) 
• 
Weight (kg) 
• 
Body Mass Index (BMI, kg/m2), calculated as Weight (kg) / Height (m)^2 
• 
Heart Rate (bpm) 
• 
Systolic Blood Pressure (mmHg) 
• 
Diastolic Blood Pressure (mmHg) 
• 
Respiratory Rate (breaths/min) 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 36 of 49 
 
 
• 
Temperature (°C) 
 
11.5.4. 
Physical Examination 
 
A listing of Physical Examination results will be provided. 
11.5.5. 
12-lead ECG 
ECG parameters will be summarized using descriptive statistics both in terms of absolute values and 
change from baseline at each visit and time point. 
The following parameters will be presented in the summary tables: 
• 
Heart Rate (bpm) 
• 
PR Interval (msec) 
• 
QRS Duration (msec) 
• 
QT Interval (msec) 
• 
QTcF Interval (msec) 
 
In addition, the following categorical analysis on QTcF interval prolongation will be presented 
according to the ICH E14 guideline: 
• 
Number (%) of subjects with QTcF > 450 msec and ≤480 msec 
• 
Number (%) of subjects with QTcF > 480 msec and ≤500 msec 
• 
Number (%) of subjects with QTcF > 500 msec 
• 
Number (%) of subjects with QTcF change from baseline > 30 msec and ≤60 msec 
• 
Number (%) of subjects with QTcF change from baseline > 60 msec 
 
Overall ECG Interpretation (Normal, Abnormal NCS, Abnormal CS) will only be listed. 
All ECG parameters will be listed. 
Results from unscheduled visits will not be included in the summary tables but will only be listed. 
 
11.5.6. 
Echocardiogram 
Echocardiogram results (ejection fraction (%) and interpretation) obtained at Screening will be 
presented by cohort and overall, separately for each study part, using summary statistics on the 
Safety Population. 
 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 37 of 49 
 
 
11.5.7. 
Safety laboratory tests 
Laboratory parameters, including haematology, chemistry and coagulation, will be summarized using 
descriptive statistics both in terms of absolute values and change from baseline at each visit. 
 
Laboratory values will be reported in SI units and will be compared to the relevant reference range in 
SI units and categorized as follows: 
• 
Low: < lower limit of the reference range 
• 
Normal: ≥ lower limit of the reference range and ≤ upper limit of the reference range 
• 
High: > upper limit of the reference range. 
 
Shift tables of laboratory parameters from baseline to the worst post-baseline low/normal/high 
categorization will be performed; in the shift tables, percentages will be calculated based on the 
number of subjects that have valid data for both baseline and at least 1 post-baseline assessment. 
 
For analysis purposes, values preceded by a “<” or “>” sign will be considered equal to the lower or 
upper limit of quantification, respectively. 
All laboratory parameters, including low/normal/high categorization, will be listed. 
Results from unscheduled visits will not be included in the summary tables but will only be listed. 
11.5.8. 
ECOG Performance Status 
ECOG PS will be summarized using frequency counts and percentages at each visit. 
In addition, shift tables of ECOG PS values from screening to End of Treatment visit will be 
presented. 
All ECOG PS values will also be listed. 
Results from unscheduled visits will not be included in the summary tables but will only be listed. 
 
11.5.9. 
Reproductive System Findings and Pregnancy Test 
Reproductive system findings (child-bearing potential, postmenopausal status, surgical sterilization) 
as well as pregnancy test results (positive/negative) at each study visit will only be listed. 
11.5.10. 
Treatment exposure and compliance 
The following parameters will be summarized using descriptive statistics: 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 38 of 49 
 
 
• 
Cumulative dose (mg) is the sum of the number of capsules taken at each occasion multiplied 
by the strength of each capsule. 
• 
Treatment duration from first intake (days) is calculated as (Last dose date – First dose date in 
run-in period + 1). 
• 
Treatment duration from Cycle 1 Day 1 (days) is calculated as (Last dose date – First dose 
date in Cycle 1 Day 1 + 1). 
• 
Actual Dose Intensity (mg/day) = [cumulative dose (mg)] / [treatment duration from first intake 
(days)] 
• 
Planned Dose Intensity (mg/day) = Total daily dose for the cohort (see Table 1). 
• 
Relative Dose Intensity (%) = [actual dose intensity (mg/day)] / [planned dose intensity 
(mg/day)] 
Study treatment administration at the site and study drug accountability as collected in the eCRF, as 
well as the daily records from the patient diary will be listed. 
 
12. Efficacy evaluations 
Efficacy evaluations are based upon the Investigator’s assessment. 
Tumor assessment will occur at Screening (for identification of baseline disease) and after every 2 
cycles of treatment thereafter. Response will be evaluated using Response Evaluation Criteria in 
Solid Tumors (RECIST) v1.1. 
After completion of the EOT visit, patients will then be followed every 90 days for survival status for 
12 months. The survival follow-up may be by telephone contact. If the patient discontinued study 
drug for reasons other than progressive disease, disease assessments should continue to be 
performed on an every 8-week basis (±1 week) through 6 months after the first study drug dose 
and then on an every 90-day basis or until, in the judgment of the Investigator, there is evidence of 
relapsed or progressive disease. 
12.1. Efficacy analysis 
12.1.1. 
Best Overall Response and Objective Response 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 39 of 49 
 
 
Best overall response (BOR) will be assessed based on reported overall lesion responses at different 
evaluation time points from the first dose of SL-901 until the first documentation of PD, according to 
the following hierarchical rules. 
 
• 
CR = at least two determinations of CR at least 4 weeks apart and before first documentation 
of PD  
• 
PR = at least two determinations of PR or better (PR followed by PR or PR followed by CR) at 
least 4 weeks apart and before first documentation of PD (and not qualifying for a CR) 
• 
SD (applicable only to patients with measurable disease at baseline) or Non-CR/non-PD 
(applicable only to patients with non-measurable disease at baseline) = at least one SD (or 
non-CR/non-PD) assessment (or better) ≥ 6 weeks after the first dose of SL-901 and before 
first documentation of PD (and not qualifying for CR or PR). 
• 
SD = unconfirmed CR/PR (i.e. one determination of CR or PR followed by PD or NE) occurring 
at least 6 weeks after the first dose of SL-901 
• 
PD = at least one documentation of PD (and not qualifying for CR, PR, SD or non-CR/non-
PD). 
• 
NE = all other cases. 
 
Objective Response (OR) is defined as confirmed BOR of CR or PR according to RECIST v1.1. 
Each patient will have an objective response status (0: no OR; 1: OR). 
OR rate (ORR) is the proportion of patients with OR in the relevant analysis set. 
Disease Control (DC) is defined as BOR of CR, PR, non-CR/non-PD or SD.  
DC rate (DCR) is the proportion of patients with DC in the relevant analysis set. 
CR rate (CRR) is the proportion of patients with a confirmed BOR of CR in the relevant analysis set. 
 
ORR, DCR and CRR by cohort and overall will be calculated along with the 2-sided 95% CI using the 
Clopper-Pearson method (exact CI for a binomial proportion as computed by default by the FREQ 
procedure using the EXACT option).  
In addition, the number and percentage of patients with BOR of CR, PR, SD, non-CR/non-PD 
(applicable only to patients with non-measurable disease at baseline), PD, and NE will be tabulated. 
These analyses will be presented by cohort both in the Efficacy and in the Per Protocol populations. 
 
All data related to target lesions, non-target lesions, new lesions and response assessment will be 
listed. 
12.1.2. 
Duration of Response 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 40 of 49 
 
 
Duration of response (DOR) is defined, for patients with OR, as the time (in months) from the first 
documentation of objective response (CR or PR) to the date of first documentation of PD. 
Duration of Complete Response (DOCR) is defined, for patients with a confirmed BOR of CR, as the 
time from the first documentation of CR to the date of first documentation of PD. 
 
DOR and DOCR will be calculated as follows: 
DOR (months) = [date of event or censoring– first date of OR +1]/30.4375 
DOCR (months) = [date of event or censoring– first date of CR +1]/30.4375 
 
DOR and DOCR will be censored at the last tumor assessment if the patient did not have disease 
progression. If a patient receives a new systemic anti-cancer therapy before disease progression, 
DOR and DOCR will be censored at the last tumor assessment before the date of initiation of new 
systemic anti-cancer therapy. In addition, patients who experience PD after ≥2 missing tumor 
assessments will be censored at the last tumor assessments prior to the missed visits. 
 
 DOR and DOCR will be analyzed by cohort using the Kaplan-Meier method, with the median, 25th 
and 75th percentiles as well as DOR and DOCR rates at 3, 6 and 12 months (and every 6 months 
thereafter until the end of follow-up or no more subjects are at risk) reported along with the 2-sided 
95% CIs calculated according to Brookmeyer and Crowley using a linear transformation 
(CONFTYPE=LINEAR in SAS Proc LIFETEST). Number and percentage of patients with event (PD) 
and censoring reasons will be presented by cohort. 
DOR and DOCR will be displayed graphically using Kaplan-Meier curves. 
These analyses will be presented by cohort both in the Efficacy and in the Per Protocol populations. 
12.1.3. 
Progression-free survival 
Progression-free survival (PFS) is defined as the time (in months) from the date of first intake of SL-
901 to the date of the first documentation of PD (per RECIST v1.1) or death due to any cause, 
whichever occurs first, regardless of whether the patients withdraws from study treatment. 
 
 
 
 
 
   
 
 
 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 41 of 49 
 
 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 42 of 49 
 
 
 
 PFS will be analyzed by cohort and overall using the Kaplan-Meier method, with the median, 25th and 
75th percentiles as well as PFS rates at 3, 6 and 12 months (and every 6 months thereafter until the 
end of follow-up or no more subjects are at risk) reported along with the 2-sided 95% CIs calculated 
according to Brookmeyer and Crowley using a linear transformation (CONFTYPE=LINEAR in SAS 
Proc LIFETEST). Number and percentage of patients with each event type (PD or death) and 
censoring reasons will be presented by cohort. 
PFS will be displayed graphically using Kaplan-Meier curves. 
These analyses will be presented by cohort both in the Efficacy and in the Per Protocol populations. 
12.1.4. 
Overall Survival 
Overall survival (OS) is defined as the time from the date of first SL-901 intake to the date of death 
due to any cause, regardless of whether the patient withdraws from study treatment or receives 
another anticancer therapy.  
OS (months) = [date of death or censoring– date of first SL-901 intake +1]/30.4375 
Patients not known to have died at the time of analysis will be censored at the last recorded date on 
which the subject was known to be alive, based on the data collected in the “Long Term Follow-up” 
eCRF. 
OS will be analyzed by cohort and overall using the Kaplan-Meier method, with the median, 25th and 
75th percentiles as well as OS rates at 12, 18 and 24 months (and every 6 months thereafter until the 
end of follow-up or no more subjects are at risk) reported along with the 2-sided 95% CIs calculated 
according to Brookmeyer and Crowley using a linear transformation (CONFTYPE=LINEAR in SAS 
Proc LIFETEST). Number and percentage of patients with event (death) and censored will be 
presented by cohort and overall. 
OS will be displayed graphically using Kaplan-Meier curves. 
These analyses will be presented by cohort both in the Efficacy and in the Per Protocol populations. 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 43 of 49 
 
 
12.2. Subgroup analyses 
Not Applicable. 
12.3. Pharmacokinetic analysis 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 44 of 49 
 
 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 45 of 49 
 
 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 46 of 49 
 
 
13. Tables, listings and figures 
13.1. Statistical Analysis Report 
The TLF (Tables, Listings and Figures) will follow the list of tables, plots, and listings agreed with the 
Study Team. 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 47 of 49 
 
 
13.2. Index of TLFs 
13.2.1. 
Tables 
Table 14.1.1.1: Analysis Populations 
 
Table 14.1.1.2: Patient Disposition 
 
Table 14.1.1.3: Critical Protocol Deviations 
 
Table 14.1.1.4: Major Protocol Deviations 
 
Table 14.1.1.5: Minor Protocol Deviations 
 
Table 14.1.2.1: Demographic Characteristics 
 
Table 14.1.2.2: Tumor History 
 
Table 14.1.2.3: Tumor Mutational Status  
Table 14.1.2.4: Medical History by SOC and PT  
Table 14.1.2.5: Concomitant Medical Conditions by SOC and PT  
Table 14.1.3.1: Prior Medications by ATC Code  
Table 14.1.3.2: Concomitant Medications by ATC Code  
Table 14.1.3.3: Prior and Concomitant Medications by ATC Code 
Table 14.1.3.4: Overview of Prior Cancer Drug Therapies 
 
Table 14.1.3.5: Prior Cancer Drug Therapies by ATC code 
 
Table 14.1.3.6: Prior Cancer Radiotherapies 
 
Table 14.1.3.7: Prior Procedures by SOC and PT 
 
Table 14.1.3.8: Concomitant Procedures by SOC and PT 
 
Table 14.1.3.9: Treatment Exposure 
 
Table 14.3.1.1.1: Summary of Treatment-Emergent Adverse Events 
 
Table 14.3.1.1.2: DLTs by SOC and PT  
Table 14.3.1.1.3: TEAEs by SOC and PT 
 
Table 14.3.1.1.4: TEAEs by Maximum CTCAE Grade, SOC and PT 
 
Table 14.3.1.1.5: TEAEs Leading to Interruption of Study Treatment by SOC and PT 
 
Table 14.3.1.1.6: TEAEs Leading to Withdrawal of Study Treatment by SOC and PT 
 
Table 14.3.1.1.7: TEAEs Leading to Dose Reduction of Study Treatment by SOC and PT  
Table 14.3.1.1.8: TEAEs Leading to Death by SOC and PT 
 
Table 14.3.1.2.1: SAEs by SOC and PT  
Table 14.3.1.2.2: SAEs by Maximum CTCAE Grade, SOC and PT 
 
Table 14.3.1.3.1: TEAEs Related to Study Treatment by SOC and PT 
 
Table 14.3.1.3.2: TEAEs Related to Study Treatment by Maximum CTCAE Grade, SOC and PT  
Table 14.3.1.3.3: Treatment-related TEAEs Leading to Interruption of Study Treatment by SOC and PT 
 
Table 14.3.1.3.4: Treatment-related TEAEs Leading to Withdrawal of Study Treatment by SOC and PT 
 
Table 14.3.1.3.5: Treatment-Related TEAEs Leading to Dose Reduction of Study Treatment by SOC and PT  
Table 14.3.1.3.6: Treatment-Related TEAEs Leading to Death by SOC and PT 
 
Table 14.3.1.4.1: Serious Treatment-related TEAEs by SOC and PT 
 
Table 14.3.1.4.2: Serious Treatment-related TEAEs by Maximum CTCAE Grade, SOC and PT 
 
Table 14.3.5.1: 12-Lead ECG by Visit 
 
Table 14.3.5.2: Categorical Analysis of 12-lead ECG 
 
Table 14.3.5.3: Hematology by Visit 
 
Table 14.3.5.4: Blood Chemistry by Visit  
Table 14.3.5.5: Coagulation by Visit 
 
Table 14.3.5.6: Hematology – Shift to Worst Post-Baseline Category 
 
Table 14.3.5.7: Blood Chemistry – Shift to Worst Post-Baseline Category  
Table 14.3.5.8: Coagulation – Shift to Worst Post-Baseline Category 
 
Table 14.3.5.9: ECOG Performance Status 
 
Table 14.3.5.10: ECOG Performance Status – Shift to Worst Post-Baseline Value 


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 48 of 49 
 
 
Table 14.3.5.11: Echocardiogram 
 
Table 14.2.1: Best Overall Response and Objective Response – Investigator’s Assessment (RECIST v1.1) 
 
Table 14.2.2: Duration of Response - Investigator’s Assessment (RECIST v1.1)  
Table 14.2.4: Duration of Complete Response - Investigator’s Assessment (RECIST v1.1) 
 
Table 14.2.6: Progression-free Survival - Investigator’s Assessment (RECIST v1.1) 
 
Table 14.2.8: Overall Survival - Investigator’s Assessment (RECIST v1.1) 
 
Table 14.4.1: SL-901 Plasma PK Concentrations by Cohort, Visit and Nominal Time  
Table 14.4.8: SL-901 Plasma PK Parameters by Cohort and Visit 
13.2.2. 
Listings 
Listing 16.2.1.1: Patient Disposition 
 
Listing 16.2.1.2: Analysis Populations 
 
Listing 16.2.2.1: Critical Protocol Deviations 
 
Listing 16.2.2.2: Major Protocol Deviations 
 
Listing 16.2.2.3: Minor Protocol Deviations 
 
Listing 16.2.4.1: Demographic Characteristics 
 
Listing 16.2.4.2: Tumor History  
Listing 16.2.4.3: Tumor Mutation Characteristics  
Listing 16.2.4.4: Medical History  
Listing 16.2.4.5: Prior Cancer Drug Therapies 
 
Listing 16.2.4.6: Prior Procedures 
 
Listing 16.2.4.7: Prior Radiotherapies 
 
Listing 16.2.4.8: Prior and Concomitant Medications 
 
Listing 16.2.4.9: Procedures 
 
Listing 16.2.4.10: Tumor Biopsy  
Listing 16.2.5.1: Treatment Administration 
 
Listing 16.2.5.2: Drug Accountability 
 
Listing 16.2.7.1: Adverse Events 
Listing 16.2.7.2: Treatment-Emergent Adverse Events 
 
Listing 16.2.7.3: Dose-Limiting Toxicities 
Listing 16.2.7.4: Treatment-Related Treatment-Emergent Adverse Events 
 
Listing 16.2.7.5: Serious Treatment-Emergent Adverse Events 
 
Listing 16.2.7.6: Serious Treatment-Related Treatment-Emergent Adverse Events 
 
Listing 16.2.8.1: Vital Signs 
 
Listing 16.2.8.2: Physical Examination  
Listing 16.2.8.3: 12-Lead ECG  
Listing 16.2.8.4: Echocardiogram 
 
Listing 16.2.8.5: Hematology 
 
Listing 16.2.8.6: Blood Chemistry 
 
Listing 16.2.8.7: Coagulation 
 
Listing 16.2.8.8: ECOG Performance Status 
 
Listing 16.2.8.9: Reproductive Status 
 
Listing 16.2.6.1: Tumor Lesions – Investigator’s Assessment (RECIST v1.1) 
 
Listing 16.2.6.2: Tumor Response – Investigator’s Assessment (RECIST v1.1) 
 
Listing 16.2.6.3: Long-Term Follow-Up Survival Status  
Listing 16.2.6.4: Duration of Response (DOR) – Investigator’s Assessment 
 
Listing 16.2.6.5: Duration of Complete Response (DOCR) – Investigator’s Assessment 
 
Listing 16.2.6.6: Progression Free Survival (PFS) – Investigator’s Assessment 
 
Listing 16.2.6.7: Overall Survival (OS)  
Listing 16.2.9.1: PK Plasma Concentrations 
 
Listing 16.2.9.2: PK Plasma Parameters  


 
 
Study code:  STML-901-0119                              Statistical Analysis Plan (SAP) 
EudraCT no.:  2019-004135-22                           Version n.1.0, 21 Jun 2023 
 
 
MR-GCS-DMST-210.A_Template – Statistical Analysis Plan                                                 Version 1, Eff. date 31-March-2022  
 
 
 
 
 
 
    
 
 
 
 
 
     Page 49 of 49 
 
 
Listing 16.2.9.3: PD Sampling  
 
13.2.3. 
Figures 
Figure 14.2.3: Kaplan-Meier Plot of Duration of Response – Investigator’s assessment (RECIST v1.1) 
Figure 14.2.5: Kaplan-Meier Plot of Duration of Complete Response – Investigator’s assessment (RECIST v1.1)  
Figure 14.2.7: Kaplan-Meier Plot of Progression-free Survival – Investigator’s assessment (RECIST v1.1)  
Figure 14.2.9: Kaplan-Meier Plot of Overall Survival – Investigator’s assessment (RECIST v1.1)  
Figure 14.4.2: SL-901 Individual Steady-State Plasma Concentration-time Curves – Linear Scale  
Figure 14.4.3: SL-901 Individual Steady-State Plasma Concentration-time Curves – Semi-Log Scale 
 
Figure 14.4.4: SL-901 Mean (±SD) Plasma Concentration-time Curves – Run-In – Linear Scale 
 
Figure 14.4.5: SL-901 Mean (±SD) Plasma Concentration-time Curves – Cycle 1 Day 15 – Linear Scale 
 
Figure 14.4.6: SL-901 Mean (±SD) Plasma Concentration-time Curves – Run-In - Semi-Log Scale 
Figure 14.4.7: SL-901 Mean (±SD) Plasma Concentration-time Curves – Cycle 1 Day 15 - Semi-Log Scale